fluorouracil has been researched along with Cholangiocellular Carcinoma in 163 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with gallbladder cancer or cholangiocarcinoma were treated with the combination of gemcitabine 1,000 mg/m(2) IV over 100 min on days 1 and 8 and capecitabine 650 mg/m(2) BID PO on days 1-14, administered every 21 days." | 9.15 | A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202. ( Ahmad, SA; Blanke, CD; El-Khoueiry, AB; Gold, PJ; Holcombe, RF; Iqbal, S; Lenz, HJ; Messino, MJ; Rankin, C, 2011) |
| "Gemcitabine based regimens have been widely used in patients with advanced cholangiocarcinoma (CC), but no standard therapy exists." | 9.15 | A Phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas. ( Jakobsen, A; Jensen, LH; Lassen, U; Rohrberg, KS; Sorensen, M; Ujmajuridze, Z, 2011) |
| "5-Fluorouracil (5-FU), a thymidylate synthase (TS) inhibitor, has been used as the first-line chemotherapeutic drug for cholangiocarcinoma (CCA)." | 8.02 | FOXM1 inhibitor, Siomycin A, synergizes and restores 5-FU cytotoxicity in human cholangiocarcinoma cell lines via targeting thymidylate synthase. ( Klinhom-On, N; Mahalapbutr, P; Obchoei, S; Sawanyawisuth, K; Seubwai, W; Wongkham, S, 2021) |
| "Gemcitabine plus platinum as the first-line chemotherapy for cholangiocarcinoma (CCA) has limited efficacy." | 8.02 | Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study. ( Cui, J; Cui, X; Gong, W; Han, X; Lau, WY; Li, H; Li, M; Li, X; Liu, Y; Ren, T; Song, X; Wang, L; Wang, X; Wu, W; Wu, X; Zhu, Y; Zou, L, 2021) |
| "Application of 5-fluorouracil (5-FU) in cholangiocarcinoma (CCA) is limited by adverse side effects and chemoresistance." | 8.02 | Anticancer effects of the combined Thai noni juice ethanolic extracts and 5-fluorouracil against cholangiocarcinoma cells in vitro and in vivo. ( Jeeunngoi, J; Ketterman, AJ; Prompipak, J; Senawong, G; Senawong, T; Sripa, B; Utaiwat, S; Woranam, K, 2021) |
| "Fluorouracil (5-FU) is the first-line chemotherapeutic drug for cholangiocarcinoma (CCA), but its efficacy has been compromised by the development of resistance." | 7.88 | FOXM1 modulates 5-fluorouracil sensitivity in cholangiocarcinoma through thymidylate synthase (TYMS): implications of FOXM1-TYMS axis uncoupling in 5-FU resistance. ( Intuyod, K; Jiramongkol, Y; Lai, CF; Lam, EW; Luvira, V; Pairojkul, C; Pinlaor, S; Saavedra-García, P; Trakansuebkul, S; Vaeteewoottacharn, K; Waraasawapati, S; Wongkham, S; Yao, S; Yong, JS; Zona, S, 2018) |
| "To establish and characterize the gemcitabine-resistant cholangiocarcinoma (CCA) cell lines, CCA KKU‑M139 and KKU‑M214 cell lines were exposed stepwisely to increasing gemcitabine (GEM)." | 7.81 | Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness. ( Boonmars, T; Hahnvajanawong, C; Jearanaikoon, P; Kanchanawat, S; Leelayuwat, C; Namwat, N; Seubwai, W; Techasen, A; Wattanawongdon, W, 2015) |
| "The aim of the present study was to investigate the role of NK4, an antagonist for hepatocyte growth factor (HGF) and the Met receptor, in regulating the response of cholangiocarcinoma (CCA) cells to 5-fluorouracil (5-FU)." | 7.79 | NK4 regulates 5-fluorouracil sensitivity in cholangiocarcinoma cells by modulating the intrinsic apoptosis pathway. ( Ge, X; Ji, G; Li, Q; Miao, L; Wang, Y; Yu, H, 2013) |
| "To determine whether expression of certain enzymes related to 5-fluorouracil (5-FU) metabolism predicts 5-FU chemosensitivity in cholangiocarcinoma (CCA)." | 7.78 | Orotate phosphoribosyl transferase mRNA expression and the response of cholangiocarcinoma to 5-fluorouracil. ( Bhudhisawasdi, V; Chaiyagool, J; Hahnvajanawong, C; Khuntikeo, N; Namwat, N; Pugkhem, A; Seubwai, W; Sripa, B; Tassaneeyakul, W, 2012) |
| "Inhibition of TP may be beneficial in decreasing angiogenesis-dependent growth and migration of cholangiocarcinoma but may diminish the response to 5-fluorouracil chemotherapy." | 7.76 | Effects of thymidine phosphorylase on tumor aggressiveness and 5-fluorouracil sensitivity in cholangiocarcinoma. ( Jearanaikoon, P; Limpaiboon, T; Miwa, M; Pairojkul, C; Sripa, B; Tantimavanich, S; Thanasai, J, 2010) |
| "We assessed the effect of purified green tea catechins on chemotherapy-induced apoptosis in KMCH, CC-LP-1 and Mz-ChA-1 human cholangiocarcinoma cells, and on chemosensitivity of Mz-ChA-1 cell xenografts in nude mice." | 7.75 | Epigallocatechin-gallate modulates chemotherapy-induced apoptosis in human cholangiocarcinoma cells. ( Braconi, C; Henson, R; Lang, M; Patel, T, 2009) |
| "We report a case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU) combined intra-arterial chemotherapy." | 7.74 | [A case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha and 5-fluorouracil combined intra-arterial chemotherapy]. ( Doki, Y; Dono, K; Kobayashi, S; Marubashi, S; Monden, M; Mori, M; Murakami, M; Nagano, H; Nakayama, M; Noda, T; Shima, T; Takeda, Y; Tomimaru, Y; Umeshita, K; Wakasa, K, 2008) |
| "Although 5-fluorouracil (5-FU) is the drug of choice for the palliative treatment of cholangiocarcinoma (CCA), resistance to the drug is a therapeutic obstacle." | 7.74 | Characterization of 5-fluorouracil-resistant cholangiocarcinoma cell lines. ( Amimanan, P; Bhudhisawasdi, V; Jearanaikoon, P; Loilome, W; Namwat, N; Sripa, B; Tassaneeyakul, W, 2008) |
| "The authors performed a retrospective analysis of all patients with hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), or gallbladder carcinoma (GBC) who were ever treated with oral capecitabine." | 7.72 | Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. ( Aguayo, A; Brown, TD; Charnsangavej, C; Curley, SA; Ellis, LM; Hassan, MM; Lozano, RD; Nooka, AK; Patt, YZ; Schnirer, II; Vauthey, JN; Wolff, RA, 2004) |
| "Capecitabine could potentially be used for secondline treatment in patients with progressive metastatic cholangiocarcinoma." | 7.71 | Capecitabine as second-line treatment for metastatic cholangiocarcinoma: a report of two cases. ( Heinemann, V; Schalhorn, A; Stemmler, J, 2002) |
| "The adjuvant therapy (AT) for biliary tract cancer (BTC) patients after surgery has always been controversial." | 6.82 | The efficacy and safety of 5-fluorouracil based adjuvant therapy in resected biliary tract cancer: A systematic review and meta-analysis. ( Cheng, Q; Gong, S; Guo, T; Lei, C; Lu, T; Lv, K; Song, S; Tian, H; Yang, K; Yang, W, 2022) |
| "The role of postoperative therapy in extrahepatic cholangiocarcinoma (EHCC) or gallbladder carcinoma (GBCA) is unknown." | 6.80 | SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. ( Alberts, SR; Ben-Josef, E; Blanke, CD; Corless, CL; Dawson, LA; El-Khoueiry, AB; Guthrie, KA; Lowy, AM; Micetich, KC; Siegel, AB; Thomas, CR; Thomas, MB; Zalupski, MM, 2015) |
| "Bile duct cancer is characterized by fast metastasis and invasion and has been regarded as one of the most aggressive tumors due to the absence of effective diagnosis at an early stage." | 5.51 | Raddeanin A promotes apoptosis and ameliorates 5-fluorouracil resistance in cholangiocarcinoma cells. ( Fan, QX; Guo, SS; Wang, Y, 2019) |
| "(Ham-1) cells both in vitro and in vivo." | 5.46 | Synergistic Effect of Forbesione From Garcinia hanburyi in Combination with 5-Fluorouracil on Cholangiocarcinoma ( Anantachoke, N; Boonmars, T; Boueroy, P; Hahnvajanawong, C; Kongsanthia, C; Reutrakul, V; Saensa-ard, S; Salao, K; Wattanawongdon, W; Wongwajana, S, 2017) |
| "There are limits to the standard treatment for cholangiocarcinoma (CCA) including drug resistance and side effects." | 5.43 | Targeted delivery of 5-fluorouracil to cholangiocarcinoma cells using folic acid as a targeting agent. ( Boonsiri, P; Daduang, J; Daduang, S; Limpaiboon, T; Ngernyuang, N; Seubwai, W, 2016) |
| "Cholangiocarcinoma is categorized into intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC)." | 5.40 | Efficacy of hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic pegylated interferon α-2b for advanced intrahepatic cholangiocarcinoma. ( Kasai, K; Kasai, Y; Kooka, Y; Miyamoto, Y; Oikawa, K; Oikawa, T; Sawara, K; Suzuki, A; Suzuki, Y; Takikawa, Y; Ushio, A, 2014) |
| " The treatment did not cause any serious adverse events, except hypercalcemia grade I, once in 72 administrations." | 5.38 | Evaluation of efficacy, safety and tolerability of high dose-intermittent calcitriol supplementation to advanced intrahepatic cholangiocarcinoma patients--a pilot study. ( Bhudhisawasdi, V; Chamadol, N; Chur-in, S; Janeklang, S; Khuntikeo, N; Kukongviriyapan, V; Pairojkul, C; Prawan, A; Pugkhem, A; Sookprasert, A; Vaeteewoottacharn, K; Wongkham, S, 2012) |
| "Capecitabine was administered orally at a dose of 1,000 mg/m(2) twice a day for 14 days, followed by a 1-week rest period." | 5.38 | Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study. ( Han, SS; Hong, EK; Kim, CM; Kim, HB; Kim, TH; Koh, YH; Lee, WJ; Park, JW; Park, SJ; Woo, SM, 2012) |
| " We determined the anticancer effects of VPA combined with 5-FU in these cell lines." | 5.37 | Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines. ( Hanaoka, J; Ikemoto, T; Imura, S; Ishibashi, H; Iwahashi, S; Mori, H; Morine, Y; Ochir, TL; Shimada, M; Utsunomiya, T, 2011) |
| "Cholangiocarcinomas are devastating cancers that are resistant to chemotherapies." | 5.36 | Resveratrol enhances the sensitivity of cholangiocarcinoma to chemotherapeutic agents. ( DeMorrow, S; Frampton, GA; Lazcano, EA; Li, H; Mohamad, A, 2010) |
| " Cholangiocellular carcinoma cells (TFK-1 cells) were treated either with 8 Gy (RTB group) or 16 Gy (RTA group) (188)Re or with (188)Re irradiation (8 Gy) combined with either gemcitabine (8 Gy/Gem) or 5-fluorouracil (8 Gy/5-FU) at a dosage of 20 microg/ml medium for 4 days and subsequently compared with an untreated control group." | 5.35 | Impact of rhenium-188, gemcitabine, and 5-fluorouracil on cholangiocellular carcinoma cells: an in vitro study. ( Bantleon, R; Farkas, E; Kehlbach, R; Werner, M; Wiesinger, B; Wiskirchen, J, 2009) |
| "The MTD of (90)Y delivered in conjunction with capecitabine in the setting of intrahepatic cholangiocarcinoma or metastatic disease confined to the liver exceeds 170 Gy." | 5.19 | Chemoradiation of hepatic malignancies: prospective, phase 1 study of full-dose capecitabine with escalating doses of yttrium-90 radioembolization. ( Benson, AB; Gates, VL; Habib, A; Hickey, R; Kircher, S; Lewandowski, RJ; Mulcahy, MF; Newman, S; Nimeiri, H; Salem, R; Vouche, M, 2014) |
| "Gemcitabine based regimens have been widely used in patients with advanced cholangiocarcinoma (CC), but no standard therapy exists." | 5.15 | A Phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas. ( Jakobsen, A; Jensen, LH; Lassen, U; Rohrberg, KS; Sorensen, M; Ujmajuridze, Z, 2011) |
| "Patients with gallbladder cancer or cholangiocarcinoma were treated with the combination of gemcitabine 1,000 mg/m(2) IV over 100 min on days 1 and 8 and capecitabine 650 mg/m(2) BID PO on days 1-14, administered every 21 days." | 5.15 | A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202. ( Ahmad, SA; Blanke, CD; El-Khoueiry, AB; Gold, PJ; Holcombe, RF; Iqbal, S; Lenz, HJ; Messino, MJ; Rankin, C, 2011) |
| " The authors evaluated 6-month survival, response, and toxicity associated with a combination of gemcitabine, 5-fluorouracil (5-FU), and leucovorin (LV) in patients with unresectable or metastatic biliary tract or gallbladder adenocarcinoma (ACA)." | 5.11 | Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. ( Al-Khatib, H; Alberts, SR; Burgart, L; Cera, PJ; Finch, TR; Flynn, PJ; Knost, JA; Levitt, R; Mahoney, MR; Tschetter, LK; Windschitl, HE, 2005) |
| "We have reported a 33% partial response rate with acceptable toxicity using weekly 24-h infusion of high-dose 5-fluorouracil (5-FU) and leucovorin (LV) in patients with far advanced biliary tract cancers (BTC)." | 5.09 | Mitomycin C with weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract and periampullar carcinomas. ( Chen, JS; Jan, YY; Liau, CT; Lin, YC, 2001) |
| " We aim to explore the roles of LncFALEC and miR-20a-5p/SHOC2 axis on the proliferation, migration, and Fluorouracil (5-FU) resistance of cholangiocarcinoma (CCA)." | 4.31 | LncRNA FALEC increases the proliferation, migration and drug resistance of cholangiocarcinoma through competitive regulation of miR-20a-5p/SHOC2 axis. ( Du, H; Hou, S; Liu, C; Yu, T; Zhang, L; Zhang, W, 2023) |
| "Application of 5-fluorouracil (5-FU) in cholangiocarcinoma (CCA) is limited by adverse side effects and chemoresistance." | 4.02 | Anticancer effects of the combined Thai noni juice ethanolic extracts and 5-fluorouracil against cholangiocarcinoma cells in vitro and in vivo. ( Jeeunngoi, J; Ketterman, AJ; Prompipak, J; Senawong, G; Senawong, T; Sripa, B; Utaiwat, S; Woranam, K, 2021) |
| "5-Fluorouracil (5-FU), a thymidylate synthase (TS) inhibitor, has been used as the first-line chemotherapeutic drug for cholangiocarcinoma (CCA)." | 4.02 | FOXM1 inhibitor, Siomycin A, synergizes and restores 5-FU cytotoxicity in human cholangiocarcinoma cell lines via targeting thymidylate synthase. ( Klinhom-On, N; Mahalapbutr, P; Obchoei, S; Sawanyawisuth, K; Seubwai, W; Wongkham, S, 2021) |
| "Gemcitabine plus platinum as the first-line chemotherapy for cholangiocarcinoma (CCA) has limited efficacy." | 4.02 | Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study. ( Cui, J; Cui, X; Gong, W; Han, X; Lau, WY; Li, H; Li, M; Li, X; Liu, Y; Ren, T; Song, X; Wang, L; Wang, X; Wu, W; Wu, X; Zhu, Y; Zou, L, 2021) |
| "Fluorouracil (5-FU) is the first-line chemotherapeutic drug for cholangiocarcinoma (CCA), but its efficacy has been compromised by the development of resistance." | 3.88 | FOXM1 modulates 5-fluorouracil sensitivity in cholangiocarcinoma through thymidylate synthase (TYMS): implications of FOXM1-TYMS axis uncoupling in 5-FU resistance. ( Intuyod, K; Jiramongkol, Y; Lai, CF; Lam, EW; Luvira, V; Pairojkul, C; Pinlaor, S; Saavedra-García, P; Trakansuebkul, S; Vaeteewoottacharn, K; Waraasawapati, S; Wongkham, S; Yao, S; Yong, JS; Zona, S, 2018) |
| "Thirteen consecutive patients with metastatic intrahepatic cholangiocarcinoma who were refractory to first-line therapy consisting of gemcitabine plus oxaliplatin-based first-line chemotherapy given intravenously via intra-arterial infusion were treated with FOLFIRI [irinotecan (180 mg/m² i." | 3.81 | FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma. ( Bengrine, L; Ghiringhelli, F; Guion-Dusserre, JF; Lorgis, V; Vincent, J, 2015) |
| "To establish and characterize the gemcitabine-resistant cholangiocarcinoma (CCA) cell lines, CCA KKU‑M139 and KKU‑M214 cell lines were exposed stepwisely to increasing gemcitabine (GEM)." | 3.81 | Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness. ( Boonmars, T; Hahnvajanawong, C; Jearanaikoon, P; Kanchanawat, S; Leelayuwat, C; Namwat, N; Seubwai, W; Techasen, A; Wattanawongdon, W, 2015) |
| " Green fluorescent protein-labeled human cholangiocarcinoma cells and cholangiocarcinomas in 24 mice were treated with (a) combination therapy with chemotherapy (gemcitabine and 5-FU) plus RF hyperthermia, (b) chemotherapy only, (c) RF hyperthermia only, or (d) phosphate-buffered saline." | 3.80 | Intrabiliary RF heat-enhanced local chemotherapy of a cholangiocarcinoma cell line: monitoring with dual-modality imaging--preclinical study. ( Kolokythas, O; Le, T; Meng, Y; Soriano, SS; Wang, H; Wei, B; Willis, P; Wu, X; Yang, X; Zhang, F; Zhang, T, 2014) |
| "Tumor control and survival of patient with advanced cholangiocarcinoma treated with gemcitabine-based and 5FU-based chemotherapy do not markedly differ." | 3.79 | Treatment outcome of palliative chemotherapy in inoperable cholangiocarcinoma in Thailand. ( Butthongkomvong, K; Jhankumpha, S; Kumdang, S; Sirachainan, E; Sukhontharot, OU, 2013) |
| "The aim of the present study was to investigate the role of NK4, an antagonist for hepatocyte growth factor (HGF) and the Met receptor, in regulating the response of cholangiocarcinoma (CCA) cells to 5-fluorouracil (5-FU)." | 3.79 | NK4 regulates 5-fluorouracil sensitivity in cholangiocarcinoma cells by modulating the intrinsic apoptosis pathway. ( Ge, X; Ji, G; Li, Q; Miao, L; Wang, Y; Yu, H, 2013) |
| "To determine whether expression of certain enzymes related to 5-fluorouracil (5-FU) metabolism predicts 5-FU chemosensitivity in cholangiocarcinoma (CCA)." | 3.78 | Orotate phosphoribosyl transferase mRNA expression and the response of cholangiocarcinoma to 5-fluorouracil. ( Bhudhisawasdi, V; Chaiyagool, J; Hahnvajanawong, C; Khuntikeo, N; Namwat, N; Pugkhem, A; Seubwai, W; Sripa, B; Tassaneeyakul, W, 2012) |
| "Cytotoxic activity of artemisinin and derivatives in the presence and absence of holo-transferrin and expression of genes involved in resistance of cancer cells were investigated in human cholangiocarcinoma (CL-6) and hepatocarcinoma (Hep-G2) cell lines in vitro." | 3.77 | Cytotoxic activity of artemisinin derivatives against cholangiocarcinoma (CL-6) and hepatocarcinoma (Hep-G2) cell lines. ( Chaijaroenkul, W; Mahavorasirikul, W; Na-Bangchang, K; Viyanant, V, 2011) |
| "Inhibition of TP may be beneficial in decreasing angiogenesis-dependent growth and migration of cholangiocarcinoma but may diminish the response to 5-fluorouracil chemotherapy." | 3.76 | Effects of thymidine phosphorylase on tumor aggressiveness and 5-fluorouracil sensitivity in cholangiocarcinoma. ( Jearanaikoon, P; Limpaiboon, T; Miwa, M; Pairojkul, C; Sripa, B; Tantimavanich, S; Thanasai, J, 2010) |
| " We evaluated the effects of these adenoviruses with 5-fluorouracil (5-FU) and/or ganciclovir (GCV) on human cholangiocarcinoma cells (HuCCT1, with mutant p53) in vitro and in vivo." | 3.75 | Oncolytic gene therapy combined with double suicide genes for human bile duct cancer in nude mouse models. ( Hamada, H; Honda, K; Kobayashi, N; Kojima, Y, 2009) |
| "We assessed the effect of purified green tea catechins on chemotherapy-induced apoptosis in KMCH, CC-LP-1 and Mz-ChA-1 human cholangiocarcinoma cells, and on chemosensitivity of Mz-ChA-1 cell xenografts in nude mice." | 3.75 | Epigallocatechin-gallate modulates chemotherapy-induced apoptosis in human cholangiocarcinoma cells. ( Braconi, C; Henson, R; Lang, M; Patel, T, 2009) |
| "We report a case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU) combined intra-arterial chemotherapy." | 3.74 | [A case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha and 5-fluorouracil combined intra-arterial chemotherapy]. ( Doki, Y; Dono, K; Kobayashi, S; Marubashi, S; Monden, M; Mori, M; Murakami, M; Nagano, H; Nakayama, M; Noda, T; Shima, T; Takeda, Y; Tomimaru, Y; Umeshita, K; Wakasa, K, 2008) |
| "Although 5-fluorouracil (5-FU) is the drug of choice for the palliative treatment of cholangiocarcinoma (CCA), resistance to the drug is a therapeutic obstacle." | 3.74 | Characterization of 5-fluorouracil-resistant cholangiocarcinoma cell lines. ( Amimanan, P; Bhudhisawasdi, V; Jearanaikoon, P; Loilome, W; Namwat, N; Sripa, B; Tassaneeyakul, W, 2008) |
| "The authors performed a retrospective analysis of all patients with hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), or gallbladder carcinoma (GBC) who were ever treated with oral capecitabine." | 3.72 | Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. ( Aguayo, A; Brown, TD; Charnsangavej, C; Curley, SA; Ellis, LM; Hassan, MM; Lozano, RD; Nooka, AK; Patt, YZ; Schnirer, II; Vauthey, JN; Wolff, RA, 2004) |
| "Capecitabine could potentially be used for secondline treatment in patients with progressive metastatic cholangiocarcinoma." | 3.71 | Capecitabine as second-line treatment for metastatic cholangiocarcinoma: a report of two cases. ( Heinemann, V; Schalhorn, A; Stemmler, J, 2002) |
| "Cholangiocarcinoma is a deadly cancer comprising very heterogenous subtypes with a limited therapeutic arsenal in all comers." | 3.01 | Cholangiocarcinoma: what are the options in all comers and how has the advent of molecular profiling opened the way to personalised medicine ? ( Edeline, J; Lièvre, A; Malka, D; Neuzillet, C; Roth, GS; Sarabi, M, 2023) |
| "The adjuvant therapy (AT) for biliary tract cancer (BTC) patients after surgery has always been controversial." | 2.82 | The efficacy and safety of 5-fluorouracil based adjuvant therapy in resected biliary tract cancer: A systematic review and meta-analysis. ( Cheng, Q; Gong, S; Guo, T; Lei, C; Lu, T; Lv, K; Song, S; Tian, H; Yang, K; Yang, W, 2022) |
| "The role of postoperative therapy in extrahepatic cholangiocarcinoma (EHCC) or gallbladder carcinoma (GBCA) is unknown." | 2.80 | SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. ( Alberts, SR; Ben-Josef, E; Blanke, CD; Corless, CL; Dawson, LA; El-Khoueiry, AB; Guthrie, KA; Lowy, AM; Micetich, KC; Siegel, AB; Thomas, CR; Thomas, MB; Zalupski, MM, 2015) |
| "Intrahepatic cholangiocellular carcinoma after curative surgery was treated with pharmacokinetic modulation chemotherapy (PMC) as adjuvant chemotherapy." | 2.74 | [Effects of pharmacokinetic modulation chemotherapy (PMC) using oral UFT and venous 5-FU infusion as adjuvant chemotherapy for intrahepatic cholangiocellular carcinoma]. ( Fukumori, D; Kamachi, H; Kamiyama, T; Matsushita, M; Nakagawa, T; Nakanishi, K; Tahara, M; Todo, S; Yokoo, H, 2009) |
| "Our results show that the regimen of gemcitabine combined with capecitabine is effective and well tolerated in patients with unresectable relapsed or metastatic carcinoma of the biliary tract." | 2.73 | [Gemcitabine combined with capecitabine in the treatment for 41 patients with relapsed or metastatic biliary tract carcinoma]. ( Chen, X; Chen, ZS; Li, J; Ouyang, XN; Xie, FW; Yu, ZY, 2008) |
| "Cholangiocarcinoma is a rare malignancy with a poor prognosis." | 2.72 | Biliary cancer: gateway to comprehensive molecular profiling. ( Sardar, M; Shroff, RT, 2021) |
| "Mitomycin C (MMC) in combination with infusional 5-fluorouracil (FU) plus folinic acid (FA) is an effective treatment for metastatic gastrointestinal cancer." | 2.71 | Pegylated liposomal doxorubicin in combination with mitomycin C, infusional 5-fluorouracil and sodium folinic acid. A phase-I-study in patients with upper gastrointestinal cancer. ( Gnad, U; Hartmann, JT; Hehlmann, R; Hochhaus, A; Hofheinz, RD; Kreil, S; Saussele, S; Weisser, A; Willer, A, 2004) |
| "The term of biliary tract cancer (BTC) refers to all tumors that arise from the biliary tract or the biliary drainage system, including the intra- and extra-hepatic bile ducts as well as the gallbladder." | 2.55 | [Chemotherapy for Biliary Tract Cancer]. ( Woo, SM, 2017) |
| "Most patients with intrahepatic cholangiocarcinoma (IH-CCA) are unresectable and treatment options are limited." | 2.52 | Intrahepatic chemotherapy for unresectable cholangiocarcinoma: review of literature and personal experience. ( Bassi, N; Bonariol, L; Bonariol, R; Caratozzolo, E; Massani, M; Morana, G; Nistri, C; Pauletti, B; Ruffolo, C, 2015) |
| "Capecitabine has been developed as a prodrug of FU, with the goal of improving tolerability and intratumor drug concentration through tumor-specific conversion to the active drug." | 2.45 | The role of capecitabine in the management of tumors of the digestive system. ( Gennatas, C; Gennatas, S; Michalaki, V, 2009) |
| "Cholangiocarcinoma is a rare malignancy arising from the bile duct epithelium with a grim prognosis." | 2.45 | Role of liver transplantation in the treatment of cholangiocarcinoma. ( Marrero, JA; Singal, A; Welling, TH, 2009) |
| "Other costs related to advanced intrahepatic cholangiocarcinoma were calculated using National Health Insurance claims data." | 1.91 | Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy. ( Chen, ZR; Chiang, NJ; Chueh, CH; Shiu, MN; Tsai, YW; Wen, YW, 2023) |
| "Our results provide preliminary evidence that HAIC based on FOLFIRI regimen is efficient and safe in some patients progressing after previous treatment." | 1.72 | The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Based on FOLFIRI for Advanced Intrahepatic Cholangiocarcinoma as Second-Line and Successive Treatment: A Real-World Study. ( Chen, Y; Huang, P; Huang, X; Shi, G; Sun, Q; Yang, G; Zhou, Y, 2022) |
| "Cholangiocarcinoma is the first most common cancer of the biliary tract." | 1.62 | In Vitro Evaluation of Rigosertib Antitumoral and Radiosensitizing Effects against Human Cholangiocarcinoma Cells. ( Cavaletti, G; Celio, L; Damian, S; Malacrida, A; Mazzaferro, V; Miloso, M; Rigolio, R, 2021) |
| "Huaier combined with 5-FU exhibited a synergistic anti-tumor effect in Huh28 cell." | 1.51 | The synergistic antitumor effect of Huaier combined with 5-Florouracil in human cholangiocarcinoma cells. ( Che, C; Dong, B; Dong, C; Fu, Z; Liang, R; Ma, K; Wang, H; Wang, X; Zhang, R; Zhao, C, 2019) |
| "Bile duct cancer is characterized by fast metastasis and invasion and has been regarded as one of the most aggressive tumors due to the absence of effective diagnosis at an early stage." | 1.51 | Raddeanin A promotes apoptosis and ameliorates 5-fluorouracil resistance in cholangiocarcinoma cells. ( Fan, QX; Guo, SS; Wang, Y, 2019) |
| "Management of advanced intrahepatic cholangiocarcinoma (iCCA) is challenging and overall survival is poor." | 1.51 | Prolonged Response to Anti-PD-1 Antibody Therapy in Chemotherapy-Refractory Cholangiocarcinoma With High Tumor Mutational Burden. ( Gbolahan, O; Hashemi-Sadraei, N; O'Neil, B, 2019) |
| "The aim of this retrospective study was to clarify the effectiveness of chemotherapy with gemcitabine combined with low-dose 5-fluorouracil and cisplatin (GFP) for advanced biliary carcinoma after hepatectomy." | 1.46 | Effect of Adjuvant Gemcitabine Combined with Low-dose 5-Fluorouracil and Cisplatin Chemotherapy for Advanced Biliary Carcinoma. ( Arakawa, Y; Ikemoto, T; Imura, S; Iwahashi, S; Morine, Y; Saito, YU; Shimada, M; Yamada, S, 2017) |
| "(Ham-1) cells both in vitro and in vivo." | 1.46 | Synergistic Effect of Forbesione From Garcinia hanburyi in Combination with 5-Fluorouracil on Cholangiocarcinoma ( Anantachoke, N; Boonmars, T; Boueroy, P; Hahnvajanawong, C; Kongsanthia, C; Reutrakul, V; Saensa-ard, S; Salao, K; Wattanawongdon, W; Wongwajana, S, 2017) |
| "There are limits to the standard treatment for cholangiocarcinoma (CCA) including drug resistance and side effects." | 1.43 | Targeted delivery of 5-fluorouracil to cholangiocarcinoma cells using folic acid as a targeting agent. ( Boonsiri, P; Daduang, J; Daduang, S; Limpaiboon, T; Ngernyuang, N; Seubwai, W, 2016) |
| "We investigated the sensitivity of intrahepatic cholangiocarcinoma (IHCCA) subtypes to chemotherapeutics and molecular targeted agents." | 1.42 | Sensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell Cultures. ( Alvaro, D; Bragazzi, MC; Cardinale, V; Carpino, G; Costantini, D; De Rose, AM; Di Matteo, S; Fraveto, A; Gaudio, E; Giuliante, F; Grazi, GL; Lustri, AM; Napoletano, C; Nevi, L; Renzi, A; Semeraro, R, 2015) |
| " In this study, we aimed to investigate the therapeutic effect of TRAIL in CCA cell lines (M213, M214 and KKU100) compared with the immortal biliary cell line, MMNK1, either alone or in combination with a subtoxic dose of 5-fluorouracil (5-FU)." | 1.42 | TRAIL in Combination with Subtoxic 5-FU Effectively Inhibit Cell Proliferation and Induce Apoptosis in Cholangiocarcinoma Cells. ( Limpaiboon, T; Sriraksa, R, 2015) |
| "Combination therapy with 5-FU and interferon-α was safe and may improve the prognosis of advanced biliary carcinomas." | 1.42 | Intraarterial 5-fluorouracil and interferon therapy is safe and effective for nonresectable biliary tract adenocarcinoma. ( Kanda, M; Kawai, T; Obi, S; Sato, S; Sato, T; Sugimoto, T; Yashima, Y, 2015) |
| "Chemoimmunotherapy has been used to treat intrahepatic cholangiocarcinoma (ICC)." | 1.40 | Immunogenic modulation of cholangiocarcinoma cells by chemoimmunotherapy. ( Gong, J; Homma, S; Ito, M; Kajihara, M; Kan, S; Koido, S; Namiki, Y; Odahara, S; Ohkusa, T; Okamoto, M; Sugiyama, H; Tajiri, H; Takakura, K; Tsukinaga, S; Yoshida, K; Yoshizaki, S; Yusa, S, 2014) |
| "Cholangiocarcinoma is categorized into intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC)." | 1.40 | Efficacy of hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic pegylated interferon α-2b for advanced intrahepatic cholangiocarcinoma. ( Kasai, K; Kasai, Y; Kooka, Y; Miyamoto, Y; Oikawa, K; Oikawa, T; Sawara, K; Suzuki, A; Suzuki, Y; Takikawa, Y; Ushio, A, 2014) |
| "Patients were eligible if they had intrahepatic cholangiocarcinoma with liver or extrahepatic metastasis and with no prior chemotherapy." | 1.39 | Retrospective analysis of survival benefits of chemotherapy for metastatic or non-resectable intrahepatic cholangiocarcinoma. ( Chauffert, B; Ghiringhelli, F; Wiazzane, N, 2013) |
| "We report a case of acute inflammatory demyelinating polyradiculoneuropathy (AIDP) that developed in a patient with cholangiocarcinoma after receiving oxaliplatin-based chemotherapy." | 1.38 | Acute inflammatory demyelinating polyradiculoneuropathy in a patient receiving oxaliplatin-based chemotherapy. ( Bae, WK; Cho, SH; Chung, IJ; Hwang, JE; Kim, MK; Nam, TS; Shim, HJ; Yoon, JY, 2012) |
| "Intrahepatic and extrahepatic cholangiocarcinoma were observed in 57 and 21 patients, respectively." | 1.38 | Chemotherapy for inoperable advanced or metastatic cholangiocarcinoma: retrospective analysis of 78 cases in a single center over four years. ( Audrain, O; Boucher, E; Boudjema, K; Le Roux, G; Manfredi, S; Mesbah, H; Pracht, M; Raoul, JL; Sulpice, L, 2012) |
| "Capecitabine was administered orally at a dose of 1,000 mg/m(2) twice a day for 14 days, followed by a 1-week rest period." | 1.38 | Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study. ( Han, SS; Hong, EK; Kim, CM; Kim, HB; Kim, TH; Koh, YH; Lee, WJ; Park, JW; Park, SJ; Woo, SM, 2012) |
| " The treatment did not cause any serious adverse events, except hypercalcemia grade I, once in 72 administrations." | 1.38 | Evaluation of efficacy, safety and tolerability of high dose-intermittent calcitriol supplementation to advanced intrahepatic cholangiocarcinoma patients--a pilot study. ( Bhudhisawasdi, V; Chamadol, N; Chur-in, S; Janeklang, S; Khuntikeo, N; Kukongviriyapan, V; Pairojkul, C; Prawan, A; Pugkhem, A; Sookprasert, A; Vaeteewoottacharn, K; Wongkham, S, 2012) |
| " We determined the anticancer effects of VPA combined with 5-FU in these cell lines." | 1.37 | Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines. ( Hanaoka, J; Ikemoto, T; Imura, S; Ishibashi, H; Iwahashi, S; Mori, H; Morine, Y; Ochir, TL; Shimada, M; Utsunomiya, T, 2011) |
| "Cholangiocarcinoma has historically represented a major contraindication to liver transplantation at many centers because of its high recurrence rate and low disease-free survival rate, even after radical surgery." | 1.37 | Neoadjuvant therapy protocol and liver transplantation in combination with pancreatoduodenectomy for the treatment of hilar cholangiocarcinoma occurring in a case of primary sclerosing cholangitis: case report with a more than 8-year disease-free survival ( Bassi, D; Boccagni, P; Boetto, R; Cillo, U; D'Amico, F; D'Amico, FE; Gringeri, E; Lodo, E; Polacco, M; Vitale, A; Zanus, G, 2011) |
| "Patients with cholangiocarcinoma or gallbladder cancer have poor overall prognosis and their management is often complex." | 1.36 | Outcome of patients receiving chemotherapy for advanced biliary tract or gallbladder carcinoma. ( Adham, M; Bancel, B; Baulieux, J; Cassier, PA; Lombard-Bohas, C; Ponchon, T; Scoazec, JY; Souquet, JC; Thevenet, C; Walter, T, 2010) |
| "Cholangiocarcinomas are devastating cancers that are resistant to chemotherapies." | 1.36 | Resveratrol enhances the sensitivity of cholangiocarcinoma to chemotherapeutic agents. ( DeMorrow, S; Frampton, GA; Lazcano, EA; Li, H; Mohamad, A, 2010) |
| "Cholangiocarcinoma is a serious public health in Thailand with increasing incidence and mortality rates." | 1.36 | Cytotoxic activity of Thai medicinal plants against human cholangiocarcinoma, laryngeal and hepatocarcinoma cells in vitro. ( Chaijaroenkul, W; Itharat, A; Mahavorasirikul, W; Na-Bangchang, K; Viyanant, V, 2010) |
| "5 Gy, representing a dose deposited in the generous, off-target area in clinical practice, resulted in a similar pharmacokinetic profile, with a 21." | 1.36 | Abdominal irradiation modulates 5-Fluorouracil pharmacokinetics. ( Chen, YJ; Hsieh, CH; Hsieh, YJ; Huang, YC; Liu, CY; Shueng, PW; Tai, HC; Tsai, TH; Wang, LY; Wu, LJ, 2010) |
| "Extrahepatic cholangiocarcinoma is a rare malignancy." | 1.35 | Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. ( Bendell, JC; Clary, BM; Clough, RW; Czito, BG; Ghafoori, AP; Hurwitz, HI; Morse, MA; Nelson, JW; Pappas, TN; Tyler, DS; Willett, CG, 2009) |
| " Cholangiocellular carcinoma cells (TFK-1 cells) were treated either with 8 Gy (RTB group) or 16 Gy (RTA group) (188)Re or with (188)Re irradiation (8 Gy) combined with either gemcitabine (8 Gy/Gem) or 5-fluorouracil (8 Gy/5-FU) at a dosage of 20 microg/ml medium for 4 days and subsequently compared with an untreated control group." | 1.35 | Impact of rhenium-188, gemcitabine, and 5-fluorouracil on cholangiocellular carcinoma cells: an in vitro study. ( Bantleon, R; Farkas, E; Kehlbach, R; Werner, M; Wiesinger, B; Wiskirchen, J, 2009) |
| "A 66-year-old man was diagnosed with hepatocellular carcinoma with Vp3 by abdominal enhanced CT." | 1.35 | [A case of successful multimodal treatment for combined hepatocellular and cholangiocarcinoma with portal venous tumor thrombus]. ( Doki, Y; Eguchi, H; Hatano, H; Kobayashi, S; Marubashi, S; Mori, M; Murakami, M; Nagano, H; Takeda, Y; Tanemura, M; Tomimaru, Y; Tomokuni, A; Wakasa, K, 2009) |
| "Cholangiocarcinoma is a malignant neoplasm arising from the biliary epithelium." | 1.34 | Effects of the anti-epidermal growth factor receptor antibody cetuximab on cholangiocarcinoma of the liver. ( Hsieh, CB; Huang, TW; Wang, CH, 2007) |
| "The high and medium dosage groups were significantly different from the control group (P<0." | 1.34 | Effects of targeting magnetic drug nanoparticles on human cholangiocarcinoma xenografts in nude mice. ( Ai, X; Chen, B; Li, H; Li, X; Tang, T; Xue, KY; Zheng, JW; Zou, SQ, 2007) |
| "The major clinical problem was the deep venous thrombosis related to the central venous catheter, which occurred in 5 patients (17%)." | 1.33 | Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors. ( Cantore, M; Caudana, R; Fiorentini, G; Lombardi, M; Mambrini, A; Nicoli, N; Pennucci, C; Rabbi, C; Sanguinetti, F; Zamagni, D, 2005) |
| "She was first diagnosed as intrahepatic cholangiocarcinoma with hepatic, paraaortic lymphnodal and bone metastasis." | 1.33 | [A case of intrahepatic cholangiocarcinoma effectively treated by hepatic arterial infusion chemotherapy]. ( Hibi, T; Higuchi, H; Hisamatsu, T; Iizuka, H; Iwasaki, E; Izumiya, M; Masaoka, T; Nagata, H; Nishizawa, T; Suzuki, H; Takaishi, H; Yamagishi, Y, 2006) |
| "Results of liver transplantation in the treatment of cholangiocarcinoma have been poor as a result of the high incidence of locoregional dissemination and tumor recurrence." | 1.31 | Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. ( Chinnakotla, S; DeRoover, A; Fox, I; Langnas, A; McCashland, T; Shaw, B; Sorrell, M; Sudan, D; Tempero, M, 2002) |
| "The first site of disease progression was local in 72% of cases." | 1.31 | Limitations of conventional doses of chemoradiation for unresectable biliary cancer. ( Brown, T; Charnsangavej, C; Crane, CH; Curley, S; Delclos, M; Janjan, NA; Macdonald, KO; Vauthey, JN; Wong, A; Yehuda, P, 2002) |
| "Cholangiocarcinoma is a virtually incurable tumor, resistant to current surgical, chemotherapy, and radiotherapy interventions." | 1.30 | Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo. ( Buchsbaum, DJ; Curiel, DT; Kancharla, SR; Mayo, MS; Pederson, LC; Stackhouse, MA; Vickers, SM, 1997) |
| "Cholangiocarcinoma is the second most common primary tumor of the liver after hepatocellular carcinoma and accounts for 5 to 25% of primary hepatic malignancies." | 1.30 | Long-term survival of a young woman with peripheral cholangiocarcinoma: a case report. ( Chabot, J; Ishak, KG; Lefkowitch, J; Marvin, MR, 1999) |
| "A patient with advanced intrahepatic cholangiocarcinoma had a tumor embolus in the right main branch of the portal vein and lymph node metastases." | 1.30 | [A case report: successful resection of advanced intrahepatic cholangiocarcinoma responding to preoperative hepatic artery infusion of 5-FU]. ( Fujita, J; Hasuike, Y; Hattori, T; Hosoki, T; Kikkawa, N; Mishima, H; Mitomo, M; Motoori, M; Nishishou, I; Sai, H; Sawamura, T, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (4.91) | 18.2507 |
| 2000's | 44 (26.99) | 29.6817 |
| 2010's | 88 (53.99) | 24.3611 |
| 2020's | 23 (14.11) | 2.80 |
| Authors | Studies |
|---|---|
| Qiu, C | 1 |
| Hu, Y | 1 |
| Wu, K | 1 |
| Yang, K | 2 |
| Wang, N | 1 |
| Ma, Y | 1 |
| Zhu, H | 1 |
| Zhang, Y | 1 |
| Zhou, Y | 2 |
| Chen, C | 1 |
| Li, S | 1 |
| Fu, L | 1 |
| Zhang, X | 2 |
| Liu, Z | 1 |
| Sribuhom, T | 1 |
| Boueroy, P | 2 |
| Hahnvajanawong, C | 5 |
| Phatchana, R | 1 |
| Yenjai, C | 1 |
| Klinhom-On, N | 1 |
| Seubwai, W | 5 |
| Sawanyawisuth, K | 2 |
| Obchoei, S | 1 |
| Mahalapbutr, P | 1 |
| Wongkham, S | 5 |
| Martviset, P | 1 |
| Panrit, L | 1 |
| Chantree, P | 1 |
| Muhamad, P | 1 |
| Na-Bangchang, K | 5 |
| Ishii, M | 1 |
| Itano, O | 1 |
| Morinaga, J | 1 |
| Shirakawa, H | 1 |
| Itano, S | 1 |
| Chen, M | 1 |
| Li, Y | 1 |
| Ma, N | 1 |
| Zang, J | 1 |
| Sonsomnuek, P | 1 |
| Tarasuk, M | 1 |
| Plengsuriyakarn, T | 1 |
| Boonprasert, K | 1 |
| Huang, P | 1 |
| Huang, X | 1 |
| Yang, G | 1 |
| Sun, Q | 1 |
| Shi, G | 1 |
| Chen, Y | 1 |
| Cosgrove, DP | 1 |
| Reese, ES | 1 |
| Fulcher, NM | 1 |
| Bobiak, SS | 1 |
| Lamy, FX | 1 |
| Allignol, A | 1 |
| Boyd, M | 1 |
| Mahmoudpour, SH | 1 |
| Roth, GS | 3 |
| Neuzillet, C | 3 |
| Sarabi, M | 3 |
| Edeline, J | 3 |
| Malka, D | 3 |
| Lièvre, A | 3 |
| Chueh, CH | 1 |
| Tsai, YW | 1 |
| Chen, ZR | 1 |
| Shiu, MN | 1 |
| Wen, YW | 1 |
| Chiang, NJ | 1 |
| Yamagata, M | 1 |
| Nakajima, T | 2 |
| Aihara, T | 1 |
| Nishijima, N | 1 |
| Tomoo, Y | 1 |
| Matsuki, G | 1 |
| Fujikawa, M | 1 |
| Ichise, N | 1 |
| Kasai, M | 1 |
| Okamoto, R | 1 |
| Ikuta, S | 1 |
| Nakamoto, Y | 1 |
| Osaki, Y | 1 |
| Yanagi, H | 1 |
| Yamanaka, N | 2 |
| Du, H | 1 |
| Hou, S | 1 |
| Zhang, L | 1 |
| Liu, C | 2 |
| Yu, T | 1 |
| Zhang, W | 2 |
| Fu, Z | 1 |
| Ma, K | 1 |
| Dong, B | 1 |
| Zhao, C | 1 |
| Che, C | 1 |
| Dong, C | 1 |
| Zhang, R | 2 |
| Wang, H | 2 |
| Wang, X | 2 |
| Liang, R | 1 |
| Wattanavises, S | 1 |
| Silsirivanit, A | 1 |
| Cha'on, U | 1 |
| Waraasawapati, S | 2 |
| Saentaweesuk, W | 1 |
| Luang, S | 1 |
| Chalermwat, C | 1 |
| Wongkham, C | 1 |
| Smart, AC | 1 |
| Goyal, L | 1 |
| Horick, N | 1 |
| Petkovska, N | 1 |
| Zhu, AX | 3 |
| Ferrone, CR | 1 |
| Tanabe, KK | 1 |
| Allen, JN | 1 |
| Drapek, LC | 1 |
| Qadan, M | 1 |
| Murphy, JE | 1 |
| Eyler, CE | 1 |
| Ryan, DP | 1 |
| Hong, TS | 1 |
| Wo, JY | 1 |
| Yang, J | 1 |
| Wang, J | 1 |
| Zhou, H | 1 |
| Wang, Y | 5 |
| Huang, H | 1 |
| Jin, H | 1 |
| Lou, Q | 1 |
| Shah, RJ | 1 |
| Oguz, S | 1 |
| Kucukaslan, H | 1 |
| Topaloglu, S | 1 |
| Ones, T | 1 |
| Baltacioglu, F | 1 |
| Cobanoglu, U | 1 |
| Calik, A | 1 |
| Permpoon, U | 1 |
| Khan, F | 1 |
| Vadevoo, SMP | 1 |
| Gurung, S | 1 |
| Gunassekaran, GR | 1 |
| Kim, MJ | 1 |
| Kim, SH | 1 |
| Thuwajit, P | 1 |
| Lee, B | 1 |
| Gaddam, S | 1 |
| Coté, GA | 1 |
| Sardar, M | 1 |
| Shroff, RT | 1 |
| Jones, O | 1 |
| Cheng, X | 1 |
| Murthy, SRK | 1 |
| Ly, L | 1 |
| Zhuang, T | 1 |
| Basadonna, G | 1 |
| Keidar, M | 1 |
| Canady, J | 1 |
| Chen, L | 1 |
| Chen, W | 1 |
| Xu, S | 1 |
| Tang, L | 1 |
| Yang, Y | 1 |
| Li, Q | 2 |
| Jiang, Q | 1 |
| Miao, L | 2 |
| Zou, L | 1 |
| Li, X | 2 |
| Wu, X | 2 |
| Cui, J | 1 |
| Cui, X | 1 |
| Song, X | 1 |
| Ren, T | 1 |
| Han, X | 1 |
| Zhu, Y | 1 |
| Li, H | 3 |
| Wu, W | 1 |
| Gong, W | 1 |
| Wang, L | 1 |
| Li, M | 1 |
| Lau, WY | 2 |
| Liu, Y | 2 |
| Prompipak, J | 1 |
| Senawong, T | 1 |
| Sripa, B | 5 |
| Ketterman, AJ | 1 |
| Utaiwat, S | 1 |
| Woranam, K | 1 |
| Jeeunngoi, J | 1 |
| Senawong, G | 1 |
| Malacrida, A | 1 |
| Rigolio, R | 1 |
| Celio, L | 1 |
| Damian, S | 1 |
| Cavaletti, G | 1 |
| Mazzaferro, V | 1 |
| Miloso, M | 1 |
| Song, S | 1 |
| Yang, W | 1 |
| Tian, H | 1 |
| Gong, S | 1 |
| Lei, C | 1 |
| Lv, K | 1 |
| Lu, T | 1 |
| Cheng, Q | 1 |
| Guo, T | 1 |
| Woo, SM | 3 |
| Morine, Y | 2 |
| Shimada, M | 2 |
| Ikemoto, T | 2 |
| Arakawa, Y | 1 |
| Iwahashi, S | 2 |
| Saito, YU | 1 |
| Yamada, S | 1 |
| Imura, S | 2 |
| Bruckner, HW | 1 |
| Gurell, D | 1 |
| Hirschfeld, A | 1 |
| Boonmars, T | 2 |
| Saensa-ard, S | 1 |
| Wattanawongdon, W | 2 |
| Kongsanthia, C | 1 |
| Salao, K | 1 |
| Wongwajana, S | 1 |
| Anantachoke, N | 1 |
| Reutrakul, V | 1 |
| Kobayashi, S | 4 |
| Terashima, T | 1 |
| Shiba, S | 1 |
| Yoshida, Y | 1 |
| Yamada, I | 1 |
| Iwadou, S | 1 |
| Horiguchi, S | 1 |
| Takahashi, H | 1 |
| Suzuki, E | 1 |
| Moriguchi, M | 1 |
| Tsuji, K | 1 |
| Otsuka, T | 1 |
| Asagi, A | 1 |
| Kojima, Y | 2 |
| Takada, R | 1 |
| Morizane, C | 1 |
| Mizuno, N | 1 |
| Ikeda, M | 1 |
| Ueno, M | 1 |
| Furuse, J | 1 |
| Srijiwangsa, P | 1 |
| Ponnikorn, S | 1 |
| Liotta, L | 1 |
| Quante, M | 1 |
| Intuyod, K | 1 |
| Saavedra-García, P | 1 |
| Zona, S | 1 |
| Lai, CF | 1 |
| Jiramongkol, Y | 1 |
| Vaeteewoottacharn, K | 3 |
| Pairojkul, C | 3 |
| Yao, S | 1 |
| Yong, JS | 1 |
| Trakansuebkul, S | 1 |
| Luvira, V | 1 |
| Pinlaor, S | 1 |
| Lam, EW | 1 |
| Miyata, T | 1 |
| Beppu, T | 2 |
| Imamura, YU | 1 |
| Hayashi, H | 2 |
| Imai, K | 1 |
| Chikamoto, A | 1 |
| Yamashita, YI | 1 |
| Fukubayashi, K | 1 |
| Ishiko, T | 2 |
| Baba, H | 2 |
| Qiu, G | 1 |
| Ma, D | 1 |
| Li, F | 1 |
| Sun, D | 1 |
| Zeng, Z | 1 |
| Bisello, S | 1 |
| Buwenge, M | 1 |
| Palloni, A | 1 |
| Autorino, R | 1 |
| Cellini, F | 1 |
| Macchia, G | 1 |
| Deodato, F | 1 |
| Cilla, S | 1 |
| Brandi, G | 1 |
| Tagliaferri, L | 1 |
| Cammelli, S | 1 |
| Valentini, V | 1 |
| Morganti, AG | 1 |
| Mattiucci, GC | 1 |
| Gbolahan, O | 1 |
| Hashemi-Sadraei, N | 1 |
| O'Neil, B | 1 |
| Guo, SS | 1 |
| Fan, QX | 1 |
| Sookprasert, A | 2 |
| Pugkhem, A | 2 |
| Khuntikeo, N | 3 |
| Chur-in, S | 1 |
| Chamadol, N | 1 |
| Prawan, A | 3 |
| Janeklang, S | 1 |
| Kukongviriyapan, V | 3 |
| Bhudhisawasdi, V | 3 |
| Lange, S | 1 |
| Lampe, J | 1 |
| Bossow, S | 1 |
| Zimmermann, M | 1 |
| Neubert, W | 1 |
| Bitzer, M | 1 |
| Lauer, UM | 1 |
| Duignan, S | 1 |
| Maguire, D | 1 |
| Ravichand, CS | 1 |
| Geoghegan, J | 1 |
| Hoti, E | 1 |
| Fennelly, D | 1 |
| Armstrong, J | 1 |
| Rock, K | 1 |
| Mohan, H | 1 |
| Traynor, O | 1 |
| Ge, X | 1 |
| Yu, H | 1 |
| Ji, G | 1 |
| Wiazzane, N | 1 |
| Chauffert, B | 1 |
| Ghiringhelli, F | 2 |
| Wirasorn, K | 1 |
| Ngamprasertchai, T | 1 |
| Pakkhem, A | 1 |
| Ungarereevittaya, P | 1 |
| Chindaprasirt, J | 1 |
| Butthongkomvong, K | 1 |
| Sirachainan, E | 1 |
| Jhankumpha, S | 1 |
| Kumdang, S | 1 |
| Sukhontharot, OU | 1 |
| Sinn, M | 1 |
| Nicolaou, A | 1 |
| Ricke, J | 1 |
| Podrabsky, P | 1 |
| Seehofer, D | 1 |
| Gebauer, B | 1 |
| Pech, M | 1 |
| Neuhaus, P | 1 |
| Dörken, B | 2 |
| Riess, H | 2 |
| Hildebrandt, B | 1 |
| Welling, TH | 2 |
| Feng, M | 1 |
| Wan, S | 1 |
| Hwang, SY | 1 |
| Volk, ML | 1 |
| Lawrence, TS | 1 |
| Zalupski, MM | 2 |
| Sonnenday, CJ | 1 |
| Kim, YI | 1 |
| Park, JW | 2 |
| Kim, BH | 1 |
| Kim, TH | 2 |
| Koh, YH | 2 |
| Lee, WJ | 2 |
| Kim, CM | 2 |
| Zeekpudsa, P | 1 |
| Senggunprai, L | 2 |
| Goldberg, SN | 1 |
| Zhang, F | 1 |
| Le, T | 1 |
| Zhang, T | 1 |
| Meng, Y | 1 |
| Wei, B | 1 |
| Soriano, SS | 1 |
| Willis, P | 1 |
| Kolokythas, O | 1 |
| Yang, X | 1 |
| Hickey, R | 1 |
| Mulcahy, MF | 1 |
| Lewandowski, RJ | 1 |
| Gates, VL | 1 |
| Vouche, M | 1 |
| Habib, A | 1 |
| Kircher, S | 1 |
| Newman, S | 1 |
| Nimeiri, H | 1 |
| Benson, AB | 2 |
| Salem, R | 1 |
| Wu, WR | 1 |
| Shi, XD | 1 |
| Zhu, MS | 1 |
| Xu, LB | 1 |
| Zeng, H | 1 |
| Kasai, K | 1 |
| Kooka, Y | 1 |
| Suzuki, Y | 1 |
| Suzuki, A | 1 |
| Oikawa, T | 1 |
| Ushio, A | 1 |
| Kasai, Y | 1 |
| Sawara, K | 1 |
| Miyamoto, Y | 1 |
| Oikawa, K | 1 |
| Takikawa, Y | 1 |
| Hong, MJ | 1 |
| Cheon, YK | 1 |
| Lee, EJ | 1 |
| Lee, TY | 1 |
| Shim, CS | 1 |
| Sio, TT | 1 |
| Martenson, JA | 1 |
| Haddock, MG | 2 |
| Novotny, PJ | 1 |
| Gores, GJ | 2 |
| Alberts, SR | 3 |
| Miller, RC | 1 |
| Heimbach, JK | 1 |
| Rosen, CB | 2 |
| Koido, S | 1 |
| Kan, S | 1 |
| Yoshida, K | 1 |
| Yoshizaki, S | 1 |
| Takakura, K | 1 |
| Namiki, Y | 1 |
| Tsukinaga, S | 1 |
| Odahara, S | 1 |
| Kajihara, M | 1 |
| Okamoto, M | 1 |
| Ito, M | 1 |
| Yusa, S | 1 |
| Gong, J | 1 |
| Sugiyama, H | 1 |
| Ohkusa, T | 1 |
| Homma, S | 1 |
| Tajiri, H | 1 |
| Patkowski, W | 1 |
| Stankiewicz, R | 1 |
| Grąt, M | 1 |
| Krasnodębski, M | 1 |
| Kornasiewicz, O | 1 |
| Krawczyk, M | 1 |
| Huang, GL | 2 |
| Shen, DY | 2 |
| Cai, CF | 1 |
| Zhang, QY | 1 |
| Ren, HY | 2 |
| Chen, QX | 1 |
| Samatiwat, P | 1 |
| Guion-Dusserre, JF | 1 |
| Lorgis, V | 1 |
| Vincent, J | 1 |
| Bengrine, L | 1 |
| Yashima, Y | 1 |
| Sato, S | 1 |
| Kawai, T | 1 |
| Sugimoto, T | 1 |
| Sato, T | 2 |
| Kanda, M | 1 |
| Obi, S | 1 |
| Hong, ZF | 1 |
| Zhao, WX | 1 |
| Yin, ZY | 1 |
| Xie, CR | 1 |
| Xu, YP | 1 |
| Chi, XQ | 1 |
| Zhang, S | 1 |
| Wang, XM | 1 |
| Li, J | 2 |
| Wang, Q | 1 |
| Lei, Z | 1 |
| Wu, D | 1 |
| Si, A | 1 |
| Wang, K | 1 |
| Wan, X | 1 |
| Yan, Z | 1 |
| Xia, Y | 1 |
| Wu, M | 1 |
| Shen, F | 1 |
| Ben-Josef, E | 1 |
| Guthrie, KA | 1 |
| El-Khoueiry, AB | 2 |
| Corless, CL | 1 |
| Lowy, AM | 1 |
| Thomas, CR | 1 |
| Dawson, LA | 1 |
| Micetich, KC | 1 |
| Thomas, MB | 1 |
| Siegel, AB | 1 |
| Blanke, CD | 2 |
| Namwat, N | 3 |
| Kanchanawat, S | 1 |
| Jearanaikoon, P | 4 |
| Leelayuwat, C | 2 |
| Techasen, A | 2 |
| Nutthasirikul, N | 1 |
| Limpaiboon, T | 4 |
| Chau-In, S | 1 |
| Massani, M | 1 |
| Nistri, C | 1 |
| Ruffolo, C | 1 |
| Bonariol, R | 1 |
| Pauletti, B | 1 |
| Bonariol, L | 1 |
| Caratozzolo, E | 1 |
| Morana, G | 1 |
| Bassi, N | 1 |
| Sriraksa, R | 1 |
| Park, KW | 1 |
| Seo, CJ | 1 |
| Yun, DY | 1 |
| Kim, MK | 2 |
| Kim, BS | 1 |
| Han, YS | 1 |
| Oh, HK | 1 |
| Lee, CH | 1 |
| Fraveto, A | 1 |
| Cardinale, V | 1 |
| Bragazzi, MC | 1 |
| Giuliante, F | 1 |
| De Rose, AM | 1 |
| Grazi, GL | 1 |
| Napoletano, C | 1 |
| Semeraro, R | 1 |
| Lustri, AM | 1 |
| Costantini, D | 1 |
| Nevi, L | 1 |
| Di Matteo, S | 1 |
| Renzi, A | 1 |
| Carpino, G | 1 |
| Gaudio, E | 1 |
| Alvaro, D | 1 |
| Konstantinidis, IT | 1 |
| Groot Koerkamp, B | 1 |
| Do, RK | 1 |
| Gönen, M | 1 |
| Fong, Y | 1 |
| Allen, PJ | 1 |
| D'Angelica, MI | 1 |
| Kingham, TP | 1 |
| DeMatteo, RP | 1 |
| Klimstra, DS | 1 |
| Kemeny, NE | 1 |
| Jarnagin, WR | 1 |
| Ngernyuang, N | 1 |
| Daduang, S | 1 |
| Boonsiri, P | 1 |
| Daduang, J | 1 |
| Kraiklang, R | 1 |
| Umezawa, K | 1 |
| Okada, S | 1 |
| Wentrup, R | 1 |
| Winkelmann, N | 1 |
| Mitroshkin, A | 1 |
| Prager, M | 1 |
| Voderholzer, W | 1 |
| Schachschal, G | 1 |
| Jürgensen, C | 1 |
| Büning, C | 1 |
| Endlicher, E | 1 |
| Schnoy, E | 1 |
| Troppmann, M | 1 |
| Rogler, G | 1 |
| Messmann, H | 1 |
| Klebl, F | 1 |
| Gelbmann, C | 1 |
| Kullmann, F | 1 |
| Chen, B | 2 |
| Kato, S | 1 |
| Takeuchi, Y | 1 |
| Wada, N | 1 |
| Morimoto, Y | 1 |
| Kuwaki, K | 1 |
| Ohnishi, H | 1 |
| Nakamura, S | 1 |
| Shiraha, H | 1 |
| Takaki, A | 1 |
| Okada, H | 1 |
| Hasuike, Y | 4 |
| Higuchi, I | 1 |
| Hosomi, S | 1 |
| Ishikawa, A | 2 |
| Akiyama, Y | 1 |
| Tanigawa, T | 1 |
| Okada, A | 1 |
| Yu, ZY | 1 |
| Ouyang, XN | 1 |
| Chen, ZS | 1 |
| Chen, X | 1 |
| Xie, FW | 1 |
| Amimanan, P | 1 |
| Loilome, W | 1 |
| Tassaneeyakul, W | 2 |
| Nelson, JW | 1 |
| Ghafoori, AP | 1 |
| Willett, CG | 1 |
| Tyler, DS | 1 |
| Pappas, TN | 1 |
| Clary, BM | 1 |
| Hurwitz, HI | 1 |
| Bendell, JC | 1 |
| Morse, MA | 1 |
| Clough, RW | 1 |
| Czito, BG | 1 |
| Noda, T | 1 |
| Nagano, H | 4 |
| Marubashi, S | 3 |
| Takeda, Y | 2 |
| Murakami, M | 2 |
| Tomimaru, Y | 3 |
| Dono, K | 2 |
| Umeshita, K | 2 |
| Nakayama, M | 1 |
| Shima, T | 1 |
| Wakasa, K | 2 |
| Monden, M | 2 |
| Doki, Y | 3 |
| Mori, M | 3 |
| Gennatas, C | 1 |
| Michalaki, V | 1 |
| Gennatas, S | 1 |
| Lang, M | 1 |
| Henson, R | 2 |
| Braconi, C | 1 |
| Patel, T | 2 |
| Honda, K | 1 |
| Hamada, H | 1 |
| Kobayashi, N | 2 |
| Singal, A | 1 |
| Marrero, JA | 1 |
| Wiesinger, B | 1 |
| Farkas, E | 1 |
| Kehlbach, R | 1 |
| Bantleon, R | 1 |
| Werner, M | 1 |
| Wiskirchen, J | 1 |
| Hatano, H | 1 |
| Tomokuni, A | 1 |
| Eguchi, H | 2 |
| Tanemura, M | 1 |
| Yokoo, H | 1 |
| Kamiyama, T | 1 |
| Nakagawa, T | 1 |
| Nakanishi, K | 1 |
| Tahara, M | 1 |
| Fukumori, D | 1 |
| Kamachi, H | 1 |
| Matsushita, M | 1 |
| Todo, S | 1 |
| Gerhardt, T | 1 |
| Rings, D | 1 |
| Höblinger, A | 1 |
| Heller, J | 1 |
| Sauerbruch, T | 1 |
| Schepke, M | 1 |
| Louvet, C | 1 |
| Tournigand, C | 1 |
| Chang, PY | 1 |
| Cheng, MF | 1 |
| Lee, HS | 1 |
| Hsieh, CB | 2 |
| Yao, NS | 1 |
| Hsieh, CH | 1 |
| Hsieh, YJ | 1 |
| Liu, CY | 1 |
| Tai, HC | 1 |
| Huang, YC | 1 |
| Shueng, PW | 1 |
| Wu, LJ | 1 |
| Wang, LY | 1 |
| Tsai, TH | 1 |
| Chen, YJ | 1 |
| Thanasai, J | 1 |
| Tantimavanich, S | 1 |
| Miwa, M | 1 |
| Nagai, K | 1 |
| Ishii, H | 1 |
| Miyoshi, N | 1 |
| Hoshino, H | 1 |
| Saito, T | 1 |
| Sekimoto, M | 1 |
| Cassier, PA | 1 |
| Thevenet, C | 1 |
| Walter, T | 1 |
| Baulieux, J | 1 |
| Scoazec, JY | 1 |
| Bancel, B | 1 |
| Adham, M | 1 |
| Souquet, JC | 1 |
| Ponchon, T | 1 |
| Lombard-Bohas, C | 1 |
| Yürek, S | 1 |
| Kreher, S | 1 |
| Salama, A | 1 |
| Frampton, GA | 1 |
| Lazcano, EA | 1 |
| Mohamad, A | 1 |
| DeMorrow, S | 1 |
| Lassen, U | 1 |
| Jensen, LH | 2 |
| Sorensen, M | 1 |
| Rohrberg, KS | 1 |
| Ujmajuridze, Z | 1 |
| Jakobsen, A | 2 |
| Mahavorasirikul, W | 2 |
| Viyanant, V | 2 |
| Chaijaroenkul, W | 2 |
| Itharat, A | 1 |
| Ishibashi, H | 1 |
| Utsunomiya, T | 1 |
| Ochir, TL | 1 |
| Hanaoka, J | 1 |
| Mori, H | 1 |
| Iqbal, S | 1 |
| Rankin, C | 1 |
| Lenz, HJ | 1 |
| Gold, PJ | 1 |
| Ahmad, SA | 1 |
| Messino, MJ | 1 |
| Holcombe, RF | 1 |
| Kitahara, H | 1 |
| Masumoto, J | 1 |
| Parker, AL | 1 |
| Maruta, F | 1 |
| Kubo, N | 1 |
| Shimizu, A | 1 |
| Akita, N | 1 |
| Miwa, S | 1 |
| Nakayama, J | 1 |
| Miyagawa, S | 1 |
| Gringeri, E | 1 |
| Bassi, D | 1 |
| D'Amico, FE | 1 |
| Boetto, R | 1 |
| Polacco, M | 1 |
| Lodo, E | 1 |
| D'Amico, F | 1 |
| Vitale, A | 1 |
| Boccagni, P | 1 |
| Zanus, G | 1 |
| Cillo, U | 1 |
| Bonet Beltrán, M | 1 |
| Roth, AD | 1 |
| Mentha, G | 1 |
| Allal, AS | 1 |
| Thrum, S | 1 |
| Lorenz, J | 1 |
| Mössner, J | 1 |
| Wiedmann, M | 1 |
| Tani, S | 1 |
| Murata, S | 1 |
| Tamura, M | 1 |
| Fukunaga, K | 1 |
| Morita, M | 1 |
| Hirata, Y | 1 |
| Iida, H | 1 |
| Kakuno, A | 1 |
| Nishigami, T | 1 |
| Lindebjerg, J | 1 |
| Ploen, J | 1 |
| Hansen, TF | 1 |
| Yoon, JY | 1 |
| Nam, TS | 1 |
| Hwang, JE | 1 |
| Shim, HJ | 1 |
| Cho, SH | 1 |
| Chung, IJ | 1 |
| Bae, WK | 1 |
| Pracht, M | 1 |
| Le Roux, G | 1 |
| Sulpice, L | 1 |
| Mesbah, H | 1 |
| Manfredi, S | 1 |
| Audrain, O | 1 |
| Boudjema, K | 1 |
| Raoul, JL | 1 |
| Boucher, E | 1 |
| Han, SS | 1 |
| Park, SJ | 1 |
| Kim, HB | 1 |
| Hong, EK | 1 |
| Chaiyagool, J | 1 |
| Croitoru, A | 1 |
| Gramaticu, I | 1 |
| Dinu, I | 1 |
| Gheorghe, L | 1 |
| Alexandrescu, S | 1 |
| Buica, F | 1 |
| Luca, I | 1 |
| Becheanu, G | 1 |
| Herlea, V | 1 |
| Simionov, I | 1 |
| Hrehoret, D | 1 |
| Lupescu, I | 1 |
| Popescu, I | 1 |
| Diculescu, M | 1 |
| Turaga, KK | 1 |
| Tsai, S | 1 |
| Wiebe, LA | 1 |
| Evans, DB | 1 |
| Gamblin, TC | 1 |
| Knox, JJ | 2 |
| Iwagami, Y | 1 |
| Kira, T | 1 |
| Hirao, S | 1 |
| Komatsu, H | 1 |
| Kanazawa, A | 1 |
| Tsukamoto, T | 1 |
| Shimizu, S | 1 |
| Mori, Y | 1 |
| Ohira, G | 1 |
| Kodai, S | 1 |
| Morimoto, J | 1 |
| Yamazoe, S | 1 |
| Yamamoto, A | 1 |
| Inoue, T | 1 |
| Yamashita, Y | 1 |
| Nishiguchi, Y | 1 |
| Ikehara, T | 1 |
| Taira, K | 1 |
| Horii, K | 1 |
| Yamazaki, O | 1 |
| Gardini, A | 1 |
| Saragoni, L | 1 |
| La Barba, G | 1 |
| Serra, L | 1 |
| Calistri, D | 1 |
| Ulivi, P | 1 |
| Casadei, A | 1 |
| Frassineti, GL | 1 |
| Garcea, D | 1 |
| Taïeb, J | 1 |
| Mitry, E | 1 |
| Boige, V | 1 |
| Artru, P | 1 |
| Ezenfis, J | 1 |
| Lecomte, T | 1 |
| Clavero-Fabri, MC | 1 |
| Vaillant, JN | 1 |
| Rougier, P | 1 |
| Ducreux, M | 1 |
| Sudan, D | 1 |
| DeRoover, A | 1 |
| Chinnakotla, S | 1 |
| Fox, I | 1 |
| Shaw, B | 1 |
| McCashland, T | 1 |
| Sorrell, M | 1 |
| Tempero, M | 1 |
| Langnas, A | 1 |
| Cantore, M | 2 |
| Rabbi, C | 2 |
| Guadagni, S | 1 |
| Zamagni, D | 2 |
| Aitini, E | 1 |
| Lee, MA | 1 |
| Woo, IS | 1 |
| Kang, JH | 1 |
| Hong, YS | 1 |
| Lee, KS | 1 |
| Hedley, D | 1 |
| Oza, A | 1 |
| Siu, LL | 1 |
| Pond, GR | 1 |
| Moore, MJ | 1 |
| Hofheinz, RD | 1 |
| Willer, A | 1 |
| Weisser, A | 1 |
| Gnad, U | 1 |
| Saussele, S | 1 |
| Kreil, S | 1 |
| Hartmann, JT | 1 |
| Hehlmann, R | 1 |
| Hochhaus, A | 1 |
| Patt, YZ | 2 |
| Hassan, MM | 1 |
| Aguayo, A | 1 |
| Nooka, AK | 1 |
| Lozano, RD | 1 |
| Curley, SA | 1 |
| Vauthey, JN | 2 |
| Ellis, LM | 1 |
| Schnirer, II | 1 |
| Wolff, RA | 1 |
| Charnsangavej, C | 3 |
| Brown, TD | 1 |
| Enjoji, M | 1 |
| Yamaguchi, K | 1 |
| Nakamuta, M | 1 |
| Nakashima, M | 1 |
| Kotoh, K | 1 |
| Tanaka, M | 1 |
| Nawata, H | 1 |
| Watanabe, T | 1 |
| Kelley, ST | 1 |
| Bloomston, M | 1 |
| Serafini, F | 1 |
| Carey, LC | 1 |
| Karl, RC | 1 |
| Zervos, E | 1 |
| Goldin, S | 1 |
| Rosemurgy, P | 1 |
| Rosemurgy, AS | 1 |
| Wada, H | 1 |
| Kondo, M | 1 |
| Yamamoto, T | 1 |
| Ota, H | 1 |
| Nakamura, M | 1 |
| Yoshioka, S | 1 |
| Damdinsuren, B | 1 |
| Yubo, Y | 1 |
| Miyamoto, A | 1 |
| Nakamori, S | 2 |
| Sakon, M | 1 |
| Al-Khatib, H | 1 |
| Mahoney, MR | 1 |
| Burgart, L | 2 |
| Cera, PJ | 1 |
| Flynn, PJ | 1 |
| Finch, TR | 1 |
| Levitt, R | 1 |
| Windschitl, HE | 1 |
| Knost, JA | 1 |
| Tschetter, LK | 1 |
| Mambrini, A | 1 |
| Fiorentini, G | 1 |
| Caudana, R | 1 |
| Pennucci, C | 1 |
| Sanguinetti, F | 1 |
| Lombardi, M | 1 |
| Nicoli, N | 1 |
| Thongprasert, S | 1 |
| Akita, H | 1 |
| Yamada, T | 1 |
| Sasaki, Y | 2 |
| Ohigashi, H | 2 |
| Ishikawa, O | 2 |
| Imaoka, S | 2 |
| Hayashi, N | 1 |
| Fukuchi, N | 1 |
| Kida, H | 1 |
| Tujie, M | 1 |
| Yoshida, T | 2 |
| Ebisui, C | 1 |
| Sakita, I | 1 |
| Koshino, T | 1 |
| Izumiyama, K | 1 |
| Koro, T | 1 |
| Fujimoto, T | 1 |
| Tai, CJ | 1 |
| Chiou, HY | 1 |
| Wu, CH | 1 |
| Pan, S | 1 |
| Liu, JD | 1 |
| Naus, PJ | 1 |
| Bleeker, G | 1 |
| Wehbe, H | 1 |
| Meng, F | 1 |
| Nishizawa, T | 1 |
| Higuchi, H | 1 |
| Takaishi, H | 1 |
| Iizuka, H | 1 |
| Izumiya, M | 1 |
| Yamagishi, Y | 1 |
| Hisamatsu, T | 1 |
| Suzuki, H | 1 |
| Masaoka, T | 1 |
| Iwasaki, E | 1 |
| Nagata, H | 1 |
| Hibi, T | 1 |
| Mizumoto, T | 1 |
| Masuda, T | 1 |
| Okabe, K | 1 |
| Baba, Y | 1 |
| Okabe, H | 1 |
| Takamori, H | 1 |
| Kanemitsu, K | 1 |
| Hiroto, M | 1 |
| Huang, TW | 1 |
| Wang, CH | 1 |
| Slupski, MW | 1 |
| Szczylik, C | 1 |
| Jasinski, MK | 1 |
| Tang, T | 1 |
| Zheng, JW | 1 |
| Xue, KY | 1 |
| Ai, X | 1 |
| Zou, SQ | 1 |
| Iyer, RV | 1 |
| Gibbs, J | 1 |
| Kuvshinoff, B | 1 |
| Fakih, M | 1 |
| Kepner, J | 1 |
| Soehnlein, N | 1 |
| Lawrence, D | 1 |
| Javle, MM | 1 |
| Hezel, AF | 1 |
| Whittington, R | 1 |
| Neuberg, D | 1 |
| Tester, WJ | 1 |
| Haller, DG | 1 |
| Jones, DV | 1 |
| Hoque, A | 1 |
| Lozano, R | 1 |
| Markowitz, A | 1 |
| Raijman, I | 1 |
| Lynch, P | 1 |
| Nakano, H | 1 |
| Furukawa, H | 1 |
| Kabuto, T | 1 |
| Kameyama, M | 1 |
| Hiratsuka, M | 1 |
| Yasuda, T | 1 |
| Iwanaga, T | 1 |
| Pederson, LC | 1 |
| Buchsbaum, DJ | 1 |
| Vickers, SM | 1 |
| Kancharla, SR | 1 |
| Mayo, MS | 1 |
| Curiel, DT | 1 |
| Stackhouse, MA | 1 |
| Takao, T | 1 |
| Nishida, M | 1 |
| Maeda, Y | 1 |
| Takao, K | 1 |
| Oka, M | 1 |
| Sanz-Altamira, PM | 1 |
| Ferrante, K | 1 |
| Jenkins, RL | 1 |
| Lewis, WD | 1 |
| Huberman, MS | 1 |
| Stuart, KE | 1 |
| Marvin, MR | 1 |
| Lefkowitch, J | 1 |
| Ishak, KG | 1 |
| Chabot, J | 1 |
| Motoori, M | 1 |
| Hattori, T | 1 |
| Fujita, J | 1 |
| Mishima, H | 1 |
| Sawamura, T | 1 |
| Nishishou, I | 1 |
| Kikkawa, N | 1 |
| Sai, H | 1 |
| Hosoki, T | 1 |
| Mitomo, M | 1 |
| De Vreede, I | 1 |
| Steers, JL | 1 |
| Burch, PA | 1 |
| Gunderson, LL | 1 |
| Garner, PD | 1 |
| Hall, LD | 1 |
| Johnstone, PA | 1 |
| Mehta, VK | 1 |
| Fisher, GA | 1 |
| Ford, JM | 1 |
| Poen, JC | 1 |
| Vierra, MA | 1 |
| Oberhelman, HA | 1 |
| Bastidas, AJ | 1 |
| Chen, JS | 1 |
| Lin, YC | 1 |
| Jan, YY | 1 |
| Liau, CT | 1 |
| Tanaka, N | 1 |
| Yamakado, K | 1 |
| Nakatsuka, A | 1 |
| Fujii, A | 1 |
| Matsumura, K | 1 |
| Takeda, K | 1 |
| Matsumoto, T | 1 |
| Sasaki, A | 1 |
| Morii, Y | 1 |
| Aramaki, M | 1 |
| Kitano, S | 1 |
| Bouras, N | 1 |
| Caudry, M | 1 |
| Saric, J | 1 |
| Bonnel, C | 1 |
| Rullier, E | 1 |
| Trouette, R | 1 |
| Demeaux, H | 1 |
| Maire, JP | 1 |
| Stemmler, J | 1 |
| Heinemann, V | 1 |
| Schalhorn, A | 1 |
| Crane, CH | 1 |
| Macdonald, KO | 1 |
| Yehuda, P | 1 |
| Brown, T | 1 |
| Curley, S | 1 |
| Wong, A | 1 |
| Delclos, M | 1 |
| Janjan, NA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Endobiliary Radiofrequency Ablation With S-1 in Patients With Unresectable Cholangiocarcinoma: A Prospective Randomized Trial With Open Label Control[NCT02592538] | 66 participants (Actual) | Interventional | 2015-12-31 | Completed | |||
| Modified FOLFIRINOX Versus Gemcitabine Plus Oxaliplatin as First-line Chemotherapy for Patients With Locally Advanced or Metastatic Cholangiocarcinoma[NCT04305288] | 100 participants (Anticipated) | Observational | 2016-01-01 | Recruiting | |||
| "TACE Combined With Target Immune Therapy for First-line Treatment Compared With Intravenous Chemotherapy in the Treatment of Unresectable Intrahepatic Cholangiocarcinoma: A Prospective, Multicenter, Open, Real-World Clinical Study"[NCT05247996] | 98 participants (Anticipated) | Interventional | 2022-03-01 | Not yet recruiting | |||
| A Clinical Trial Phase II of Calcitriol in Combination With 5-fluorouracil, Mitomycin C and Leucovorin in an Open Label-non-randomized Study to Evaluate the Tumor Response in Patients With Advanced Intrahepatic Cholangiocarcinoma[NCT01039181] | Phase 2 | 28 participants (Anticipated) | Interventional | 2010-01-31 | Not yet recruiting | ||
| A Phase 2 Study of Low-Dose Fractionated Radiation Therapy to the Whole Liver in Combination With Gemcitabine and Cisplatin in Locally Advanced Mass-Forming Intrahepatic Cholangiocarcinoma[NCT02254681] | Phase 2 | 6 participants (Actual) | Interventional | 2014-09-30 | Terminated (stopped due to lack of funding) | ||
| UPCC 04219 Phase 2 Study of Capecitabine-Temozolomide(CapTem) With Yttrium-90 Radioembolization in the Treatment of Patients With Unresectable Metastatic Grade 2 Neuroendocrine Tumors[NCT04339036] | Phase 2 | 50 participants (Anticipated) | Interventional | 2021-10-07 | Recruiting | ||
| Efficacy and Safety of Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma[NCT04059562] | Phase 2 | 28 participants (Anticipated) | Interventional | 2021-10-28 | Active, not recruiting | ||
| A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)[NCT00789958] | Phase 2 | 105 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| A Randomized Controlled, Open Labeled, Two Arm, Study of Addition of Everolimus to Standard of Care in Carcinoma Gallbladder[NCT05833815] | Phase 2/Phase 3 | 56 participants (Anticipated) | Interventional | 2022-11-01 | Recruiting | ||
| A Phase II Trial of Gemcitabine (NSC-613327) and Capecitabine (NSC-712807) in Patients With Unresectable or Metastatic Gallbladder or Cholangiocarcinoma[NCT00033540] | Phase 2 | 57 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma[NCT00779454] | Phase 2 | 72 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| Prospective Registry Study of Neoadjuvant Therapy in Conjunction With Liver Transplantation for Cholangiocarcinoma[NCT00301379] | 59 participants (Actual) | Observational | 2005-08-12 | Terminated (stopped due to Low accrual) | |||
| A Single-Arm Nonrandomized Phase II Study of Liver Transplantation in Locally Advanced Unresectable Non-Metastatic Intrahepatic Cholangiocarcinoma Treated With Neoadjuvant Systemic Therapy[NCT06140134] | 30 participants (Anticipated) | Observational [Patient Registry] | 2023-12-31 | Not yet recruiting | |||
| Randomized Phase 2 Study of Capecitabine vs Gemcistabine Plus Cisplatin in Patients With Resected Extrahepatic Cholangiocarcinoma With Regional Lymph Node Metastasis[NCT03079427] | Phase 2 | 101 participants (Actual) | Interventional | 2017-05-15 | Completed | ||
| Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320] | Phase 2 | 200 participants (Actual) | Interventional | 2015-10-05 | Active, not recruiting | ||
| Phase II Trial Of Gemcitabine, 5-Fluorouracil, And Leucovorin In Patients With Measurable Unresectable Or Metastatic Biliary Tract Carcinoma (Intrahepatic, Extrahepatic, Ampulla Of Vater) And Gallbladder Carcinoma[NCT00009893] | Phase 2 | 42 participants (Actual) | Interventional | 2001-05-31 | Completed | ||
| Phase II Trial of Gemcitabine and S-1 for Patients With Advanced Biliary Tract Cancer[NCT02146703] | Phase 2 | 38 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| Oxaliplatin Plus Gemcitabine Versus Capecitabine Alone as Adjuvant Treatment in the Prevention of Recurrence of Intrahepatic Cholangiocarcinoma[NCT02548195] | Phase 3 | 286 participants (Anticipated) | Interventional | 2015-07-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To determine the number of participants with Intrahepatic disease progression assessed by MRI of the abdomen with intravenous gadolinium contrast using RECIST criteria. (NCT02254681)
Timeframe: From date of first treatment until date of first documented progression or date of death from any cause, which ever comes first, assessed up to 24 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 6 |
To determine the number of participants with Intrahepatic recurrence assessed by RECIST criteria using MRI of the abdomen with intravenous gadolinium contrast. (NCT02254681)
Timeframe: From date of partial hepatectomy until date of first documented recurrence or date of death from any cause, assessed up to 24 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 1 |
Measured post-operative complications include (but not limited to) bile leak, liver failure, ascites, infection, any organ failure or insufficiency, venous thromboembolism, and mortality. (NCT02254681)
Timeframe: up to 90 days after partial hepatectomy
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 1 |
Disease-free survival is calculated from date of registration to date of first documentation of relapse or death due to any cause. Patients last known to be alive are censored at date of last contact. (NCT00789958)
Timeframe: Up to 2 years from registration
| Intervention | percentage of participants (Number) |
|---|---|
| Adjuvant Chemotherapy + Chemoradiotherapy | 52 |
Local relapse is any evidence of new disease within the primary tumor bed or the regional (retroperitoneal, celiac, and portal vein nodes) lymphatics (these areas are to be encompassed within the radiation fields). (NCT00789958)
Timeframe: Up to 2 years from registration
| Intervention | percentage of participants (Number) |
|---|---|
| Adjuvant Chemotherapy + Chemoradiotherapy | 11 |
Time to death is calculated from date of registration to date of death due to any cause. Patients last known to be alive are censored at date of last contact. (NCT00789958)
Timeframe: Up to 2 years from registration
| Intervention | percentage of participants (Number) |
|---|---|
| Adjuvant Chemotherapy + Chemoradiotherapy | 65 |
Disease-free survival is calculated from date of registration to date of first documentation of relapse or death due to any cause. Patients last known to be alive are censored at date of last contact. (NCT00789958)
Timeframe: Up to 2 years from registration
| Intervention | percentage of participants (Number) |
|---|---|
| Patients With Negative Margins of Resection (R0) | 54 |
| Patients w/Microscopically Positive Margin of Resection (R1) | 48 |
Local relapse is any evidence of new disease within the primary tumor bed or the regional (retroperitoneal, celiac, and portal vein nodes) lymphatics (these areas are to be encompassed within the radiation fields). (NCT00789958)
Timeframe: Up to 2 years from registration
| Intervention | percentage of participants (Number) |
|---|---|
| Patients With Negative Margins of Resection (R0) | 9 |
| Patients w/Microscopically Positive Margin of Resection (R1) | 16 |
Time to death is calculated from date of registration to date of death due to any cause. Patients last known to be alive are censored at date of last contact. (NCT00789958)
Timeframe: Up to 2 years from registration
| Intervention | percentage of participants (Number) |
|---|---|
| Patients With Negative Margins of Resection (R0) | 67 |
| Patients w/Microscopically Positive Margin of Resection (R1) | 60 |
Only adverse events that are possibly, probably or definitely related to study drug are reported. (NCT00789958)
Timeframe: Up to 5 years
| Intervention | Participants (Number) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anorexia | Cardiac troponin I (cTnI) | Constipation | Dehydration | Diarrhea | Fatigue (asthenia, lethargy, malaise) | Febrile neutropenia | Hemoglobin | Hemorrhage, GI - Duodenum | Hemorrhage, GI - Lower GI NOS | Hypotension | Lung Infection w/normal ANC or Gr 1-2 neutrophils | Skin Infection w/normal ANC or Gr 1-2 neutrophils | Infection-Other (Specify) | Leukocytes (total WBC) | Lymphopenia | Mucositis/stomatitis (clinical exam) - Oral cavity | Neuropathy: sensory | Neutrophils/granulocytes (ANC/AGC) | Phosphate, serum-low (hypophosphatemia) | Platelets | Potassium, serum-low (hypokalemia) | Rash/desquamation | Rash: hand-foot skin reaction | Sodium, serum-low (hyponatremia) | Syncope (fainting) | Thrombosis/embolism (vascular access-related) | Thrombosis/thrombus/embolism | Ulcer, GI - Duodenum | Ventricular arrhythmia - Ventricular tachycardia | |
| Adjuvant Chemotherapy + Chemoradiotherapy | 1 | 1 | 1 | 1 | 6 | 4 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 6 | 2 | 1 | 35 | 1 | 2 | 2 | 1 | 10 | 1 | 1 | 1 | 1 | 1 | 1 |
Measured from time of registration to death, or last contact date (NCT00033540)
Timeframe: All patients will be followed until death or three years after registration, whichever is first.
| Intervention | months (Median) |
|---|---|
| Capecitabine + Gemcitabine | 7 |
Only eligible patients who received treatment were evaluable for response and survival outcomes. (NCT00033540)
Timeframe: 1-20 months
| Intervention | participants (Number) | |
|---|---|---|
| Eligible | Eligible and Analyzable | |
| Capecitabine + Gemcitabine | 54 | 52 |
To evaluate in a preliminary fashion relevant prognostic markers in gallbladder and cholangiocarcinoma which may have prognostic implications as predictors of survival. Overall survival measured from time of registration to death, or last contact date. (NCT00033540)
Timeframe: All patients will be followed until death or three years after registration, whichever is first.
| Intervention | months (Median) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TS 3' +/+ (N=14) | TS 3' +/- (N=6) | TS 3' -/- (N=2) | TS 5' Low functional significance (N=16) | TS 5' Intermediate functional significance (N=16) | MTHFR C677T - C/C (N=11) | MTHFR C677T - C/T (N=11) | MTHFR A1298C - A/A (N=11) | MTHFR A1298C - A/C (N=8) | MTHFR A1298C - C/C (N=3) | RRMI G/A - G/G (N=9) | RRMI G/A - G/A (N=10) | RRMI G/A - A/A (N=3) | CDA A79C - A/A (N=8) | CDA A79C - A/C (N=12) | CDA A79C - C/C (N=1) | |
| Capecitabine + Gemcitabine | 7 | 7 | 9 | 9 | 7 | 6 | 7 | 7 | 4 | 9 | 7 | 9 | 5 | 4 | 7 | NA |
Adverse Events (AEs) are reported by the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0. Any CTCAE 3.0 event of Grade 3 (severe), Grade 4 (life threatening) or Grade 5 (fatal) which were deemed to be related to protocol treatment are included. For each patient, worst grade of each event type is reported. (NCT00033540)
Timeframe: Patients were assessed for adverse events 3 weeks after starting treatment. Assessments for adverse events continued every 3 weeks for the duration of protocol treatment.
| Intervention | Participants (Number) | |||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALT, SGPT (serum glutamic pyruvic transaminase) | AST,SGOT (serum glutamic oxaloacetic transaminase) | Albumin, serum-low (hypoalbuminemia) | Alkaline phosphatase | Anorexia | Ascites (non-malignant) | Bilirubin (hyperbilirubinemia) | Constipation | Creatinine | Dehydration | Diarrhea | Dysphagia (difficulty swallowing) | Fatigue (asthenia, lethargy, malaise) | Hemoglobin | Hemolysis | Hemorrhage, GI - Esophagus | Infection w/Grade 3-4 neutrophils - Upper airway | Infection with normal ANC or Grade 1-2 neutrophils | Leukocytes (total WBC) | Mucositis/stomatitis (clinical exam) - Oral cavity | Mucositis/stomatitis (function/symp)-Oral cavity | Muscle weakness (not due to neuropathy) | Nausea | Neutrophils/granulocytes (ANC/AGC) | Pain - Abdomen NOS | Pain - Joint | Pain - Muscle | Pain - Tumor pain | Platelets | Potassium, serum-low (hypokalemia) | Rash: hand-foot skin reaction | Supraventricular nodal arrhythmia | Thrombosis/thrombus/embolism | Vomiting | |
| Gemcitabine and Capecitabine | 1 | 5 | 1 | 5 | 2 | 1 | 4 | 1 | 1 | 3 | 1 | 1 | 8 | 6 | 1 | 1 | 1 | 1 | 9 | 1 | 1 | 1 | 3 | 16 | 2 | 1 | 1 | 1 | 12 | 2 | 4 | 1 | 1 | 2 |
Complete Response (CR) is complete disappearance of all measurable and non-measurable disease. No new lesions, no disease related symptoms. Normalization of markers and other abnormal lab values. Partial Response (PR) is greater than or equal to 30% decrease under baseline of the sum of longest diameters of all target measurable lesions. No unequivocal progression of non-measurable disease. No new lesions. Confirmation of CR or PR means a repeat scan at least 4 weeks apart documented before progression or symptomatic deterioration. Progression is 20% increase in sum of longest diameters of target measurable lesions over smallest sum observed and/or unequivocal progression of non-measurable disease and/or appearance of new lesion/site or death due to disease without prior documentation of progression and without symptomatic deterioration. Symptomatic deterioration is global deterioration of health status requiring discontinuation of treatment without objective evidence of progression. (NCT00033540)
Timeframe: Patients assessed at least every six weeks while on protocol treatment
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Confirmed Partial Response | Unconfirmed Partial Response | Stable Disease | Progression | Symptomatic Deterioration | Early Death | Inadequate Assessment | |
| Capecitabine + Gemcitabine | 7 | 6 | 12 | 15 | 3 | 1 | 8 |
10 reviews available for fluorouracil and Cholangiocellular Carcinoma
| Article | Year |
|---|---|
Cholangiocarcinoma: what are the options in all comers and how has the advent of molecular profiling opened the way to personalised medicine ?
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Fluorouracil; Humans; Precision M | 2023 |
Cholangiocarcinoma: what are the options in all comers and how has the advent of molecular profiling opened the way to personalised medicine ?
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Fluorouracil; Humans; Precision M | 2023 |
Cholangiocarcinoma: what are the options in all comers and how has the advent of molecular profiling opened the way to personalised medicine ?
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Fluorouracil; Humans; Precision M | 2023 |
Cholangiocarcinoma: what are the options in all comers and how has the advent of molecular profiling opened the way to personalised medicine ?
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Fluorouracil; Humans; Precision M | 2023 |
Biliary cancer: gateway to comprehensive molecular profiling.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplat | 2021 |
The efficacy and safety of 5-fluorouracil based adjuvant therapy in resected biliary tract cancer: A systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Bilia | 2022 |
[Chemotherapy for Biliary Tract Cancer].
Topics: Antineoplastic Agents; Bevacizumab; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycyt | 2017 |
Intrahepatic chemotherapy for unresectable cholangiocarcinoma: review of literature and personal experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma | 2015 |
A case of unresectable combined hepatocellular cholangiocarcinoma showing favorable response to LFP therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, Hepatocellular; Chol | 2016 |
The role of capecitabine in the management of tumors of the digestive system.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms | 2009 |
Role of liver transplantation in the treatment of cholangiocarcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms | 2009 |
The role of chemotherapy in cholangiocarcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; | 2005 |
Systemic therapy for biliary tract cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycy | 2008 |
23 trials available for fluorouracil and Cholangiocellular Carcinoma
| Article | Year |
|---|---|
Hypofractionated Radiation Therapy for Unresectable/Locally Recurrent Intrahepatic Cholangiocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Bile Duct Neoplasms; Cholangiocarcinoma; Combined Modality Therapy; | 2020 |
Endoscopic radiofrequency ablation plus a novel oral 5-fluorouracil compound versus radiofrequency ablation alone for unresectable extrahepatic cholangiocarcinoma.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Extrah | 2020 |
[Adjuvant chemotherapy with Capecitabine as new standard for resected cholangiocarcinomas - a look at the BILCAP trial].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cholangi | 2018 |
Interventionally implanted port catheter systems for hepatic arterial infusion of chemotherapy in patients with primary liver cancer: a phase II-study (NCT00356161).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrah | 2013 |
Chemoradiation of hepatic malignancies: prospective, phase 1 study of full-dose capecitabine with escalating doses of yttrium-90 radioembolization.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Chemoradiotherapy; Cholangiocarcinoma; Deoxycytidine; | 2014 |
SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; | 2015 |
SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; | 2015 |
SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; | 2015 |
SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; | 2015 |
[Gemcitabine combined with capecitabine in the treatment for 41 patients with relapsed or metastatic biliary tract carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrah | 2008 |
[Effects of pharmacokinetic modulation chemotherapy (PMC) using oral UFT and venous 5-FU infusion as adjuvant chemotherapy for intrahepatic cholangiocellular carcinoma].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pr | 2009 |
A Phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrah | 2011 |
A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; | 2011 |
Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2012 |
Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2012 |
Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2012 |
Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2012 |
Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2002 |
Intra-arterial hepatic chemotherapy combined with continuous infusion of 5-fluorouracil in patients with metastatic cholangiocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; Cisplatin; Disease Progres | 2002 |
Epirubicin, cisplatin, and protracted infusion of 5-FU (ECF) in advanced intrahepatic cholangiocarcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; Cisplatin; Drug Adm | 2004 |
Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bi | 2004 |
Pegylated liposomal doxorubicin in combination with mitomycin C, infusional 5-fluorouracil and sodium folinic acid. A phase-I-study in patients with upper gastrointestinal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; Dox | 2004 |
Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2005 |
Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2005 |
Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2005 |
Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2005 |
A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct N | 2007 |
Protracted intravenous fluorouracil infusion with radiation therapy in the management of localized pancreaticobiliary carcinoma: a phase I Eastern Cooperative Oncology Group Trial.
Topics: Adult; Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Combined Modality Th | 1995 |
Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neop | 1996 |
A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Ca | 1998 |
Adjuvant chemoradiotherapy for "unfavorable" carcinoma of the ampulla of Vater: preliminary report.
Topics: Actuarial Analysis; Ampulla of Vater; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Chola | 2001 |
Mitomycin C with weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract and periampullar carcinomas.
Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Bilia | 2001 |
130 other studies available for fluorouracil and Cholangiocellular Carcinoma
| Article | Year |
|---|---|
Synthesis and biological evaluation of allylated mono-carbonyl analogues of curcumin (MACs) as anti-cancer agents for cholangiocarcinoma.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cholangiocarcino | 2016 |
Benzoyltyramine Alkaloids Atalantums A-G from the Peels of Atalantia monophylla and Their Cytotoxicity against Cholangiocarcinoma Cell Lines.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholang | 2017 |
FOXM1 inhibitor, Siomycin A, synergizes and restores 5-FU cytotoxicity in human cholangiocarcinoma cell lines via targeting thymidylate synthase.
Topics: Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cell Proliferation; Cell | 2021 |
Suppression of Cholangiocarcinoma Cell Growth and Proliferation by Atractylodes lancea (Thunb) DC. through ERK-Signaling Cascade.
Topics: Antineoplastic Agents; Atractylodes; Bile Duct Neoplasms; Cell Growth Processes; Cell Line, Tumor; C | 2021 |
Potential efficacy of hepatic arterial infusion chemotherapy using gemcitabine, cisplatin, and 5-fluorouracil for intrahepatic cholangiocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chola | 2022 |
Mesenchymal stem cell‑derived exosomes loaded with 5‑Fu against cholangiocarcinoma
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Exosomes; Fluorouracil; Humans; M | 2022 |
Apoptotic and Anti-metastatic Effects of Atractylodes lancea (Thunb.) DC. in a Hamster Model of Cholangiocarcinoma.
Topics: Animals; Atractylodes; bcl-2-Associated X Protein; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Ca | 2022 |
The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Based on FOLFIRI for Advanced Intrahepatic Cholangiocarcinoma as Second-Line and Successive Treatment: A Real-World Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carci | 2022 |
Real-world outcomes among patients with advanced or metastatic biliary tract cancers initiating second-line treatment.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic | 2023 |
Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy.
Topics: Biomarkers; Cholangiocarcinoma; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Fluorouracil; Hu | 2023 |
[Two Cases of Elderly Patients with Giant Intrahepatic Cholangiocarcinoma Treated with Multidisciplinary Therapy including Ablation Therapy].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile D | 2022 |
LncRNA FALEC increases the proliferation, migration and drug resistance of cholangiocarcinoma through competitive regulation of miR-20a-5p/SHOC2 axis.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cell Movement; Cell Proliferation; | 2023 |
The synergistic antitumor effect of Huaier combined with 5-Florouracil in human cholangiocarcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Chol | 2019 |
Increase of MAL-II Binding Alpha2,3-Sialylated Glycan Is Associated with 5-FU Resistance and Short Survival of Cholangiocarcinoma Patients.
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Cell Line, Tumor; Cell Proliferation; Cholangi | 2019 |
Is it Possible to Increase Survival of Patients with Intrahepatic Cholangiocarcinoma? A Case Report.
Topics: Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chemoradiotherapy, Adjuvant; Cholangiocarcinoma | 2021 |
Inhibition of Tumor Growth against Chemoresistant Cholangiocarcinoma by a Proapoptotic Peptide Targeting Interleukin-4 Receptor.
Topics: Animals; Apoptosis; Bile Duct Neoplasms; Carcinogenesis; Cell Line, Tumor; Cholangiocarcinoma; Drug | 2020 |
The importance of the "endoscopic oncologist" in the treatment of nonoperable cholangiocarcinoma.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Fluorouracil; Humans; Oncologists | 2020 |
The synergistic effect of Canady Helios cold atmospheric plasma and a FOLFIRINOX regimen for the treatment of cholangiocarcinoma in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cholangiocarcinoma; Dose-Response | 2021 |
The ATO/miRNA-885-5p/MTPN axis induces reversal of drug-resistance in cholangiocarcinoma.
Topics: Antineoplastic Agents; Arsenic Trioxide; Bile Duct Neoplasms; Cell Line; Cell Line, Tumor; Cell Surv | 2021 |
Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; Deoxycytidine; Fema | 2021 |
Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; Deoxycytidine; Fema | 2021 |
Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; Deoxycytidine; Fema | 2021 |
Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; Deoxycytidine; Fema | 2021 |
Anticancer effects of the combined Thai noni juice ethanolic extracts and 5-fluorouracil against cholangiocarcinoma cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinom | 2021 |
In Vitro Evaluation of Rigosertib Antitumoral and Radiosensitizing Effects against Human Cholangiocarcinoma Cells.
Topics: Antineoplastic Agents; Autophagy; Bile Duct Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Movement; | 2021 |
Effect of Adjuvant Gemcitabine Combined with Low-dose 5-Fluorouracil and Cisplatin Chemotherapy for Advanced Biliary Carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Chemotherapy, Adjuvant; C | 2017 |
Bevacizumab Added to Moderate-dose Chemotherapy for Refractory Uterine Cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols | 2018 |
Synergistic Effect of Forbesione From Garcinia hanburyi in Combination with 5-Fluorouracil on Cholangiocarcinoma
Topics: Animals; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Cholangiocarcinoma; Cricetinae; Drug | 2017 |
Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; | 2018 |
Effect of β-Eudesmol on NQO1 suppression-enhanced sensitivity of cholangiocarcinoma cells to chemotherapeutic agents.
Topics: Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Cell Line, Tumor; Cell Movement; Cholangiocar | 2018 |
FOXM1 modulates 5-fluorouracil sensitivity in cholangiocarcinoma through thymidylate synthase (TYMS): implications of FOXM1-TYMS axis uncoupling in 5-FU resistance.
Topics: Apoptosis; Bile Duct Neoplasms; Cell Line, Tumor; Cell Survival; Cholangiocarcinoma; Drug Resistance | 2018 |
A 12-year Recurrence-free Survival After Multidisciplinary Treatment for a Patient With Combined Hepatocellular-Cholangiocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, Hepatocellular; Chol | 2019 |
lnc-PKD2-2-3, identified by long non-coding RNA expression profiling, is associated with pejorative tumor features and poor prognosis, enhances cancer stemness and may serve as cancer stem-cell marker in cholangiocarcinoma.
Topics: Bile Duct Neoplasms; Biomarkers, Tumor; Cell Line, Tumor; Cholangiocarcinoma; Drug Resistance, Neopl | 2019 |
Radiotherapy or Chemoradiation in Unresectable Biliary Cancer: A Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Brachytherapy; | 2019 |
Prolonged Response to Anti-PD-1 Antibody Therapy in Chemotherapy-Refractory Cholangiocarcinoma With High Tumor Mutational Burden.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bile Duc | 2019 |
Raddeanin A promotes apoptosis and ameliorates 5-fluorouracil resistance in cholangiocarcinoma cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Bile Duct Neoplasms; Cell Line, Tumor; Cell Movement; | 2019 |
Evaluation of efficacy, safety and tolerability of high dose-intermittent calcitriol supplementation to advanced intrahepatic cholangiocarcinoma patients--a pilot study.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepat | 2012 |
A novel armed oncolytic measles vaccine virus for the treatment of cholangiocarcinoma.
Topics: Animals; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinoma; Fluorouracil; Genetic Therapy; H | 2013 |
Neoadjuvant chemoradiotherapy followed by liver transplantation for unresectable cholangiocarcinoma: a single-centre national experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Brachyt | 2014 |
NK4 regulates 5-fluorouracil sensitivity in cholangiocarcinoma cells by modulating the intrinsic apoptosis pathway.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Caspase 3 | 2013 |
Retrospective analysis of survival benefits of chemotherapy for metastatic or non-resectable intrahepatic cholangiocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; | 2013 |
Adjuvant chemotherapy in resectable cholangiocarcinoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; | 2013 |
Treatment outcome of palliative chemotherapy in inoperable cholangiocarcinoma in Thailand.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; | 2013 |
Neoadjuvant stereotactic body radiation therapy, capecitabine, and liver transplantation for unresectable hilar cholangiocarcinoma.
Topics: Aged; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Cholangiocarcinoma; Cholangitis, Scler | 2014 |
Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for advanced-stage unresectable intrahepatic cholangiocarcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrah | 2013 |
Suppression of NAD(P)H-quinone oxidoreductase 1 enhanced the susceptibility of cholangiocarcinoma cells to chemotherapeutic agents.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Bile Duct Neoplasms; Cell Line, Tumor; Cell Pr | 2014 |
Science to practice: Can we turn the undesired heating effects of MR imaging into effective cancer therapies?
Topics: Animals; Bile Duct Neoplasms; Cholangiocarcinoma; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; | 2014 |
Intrabiliary RF heat-enhanced local chemotherapy of a cholangiocarcinoma cell line: monitoring with dual-modality imaging--preclinical study.
Topics: Animals; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinoma; Chromatography, High Pressure Li | 2014 |
Notch1 is overexpressed in human intrahepatic cholangiocarcinoma and is associated with its proliferation, invasiveness and sensitivity to 5-fluorouracil in vitro.
Topics: Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Movement; Cell Proliferation; Cholangiocar | 2014 |
Efficacy of hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic pegylated interferon α-2b for advanced intrahepatic cholangiocarcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antivi | 2014 |
Long-term outcome of photodynamic therapy with systemic chemotherapy compared to photodynamic therapy alone in patients with advanced hilar cholangiocarcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrah | 2014 |
Outcome of Transplant-fallout Patients With Unresectable Cholangiocarcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Brachytherapy; Capecitabine; Chem | 2016 |
Immunogenic modulation of cholangiocarcinoma cells by chemoimmunotherapy.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Bile Duct Neoplas | 2014 |
Poor outcomes after liver transplantation in patients with incidental cholangiocarcinoma irrespective of tumor localization.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic | 2014 |
β-escin reverses multidrug resistance through inhibition of the GSK3β/β-catenin pathway in cholangiocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; beta | 2015 |
Repression of Nrf2 enhances antitumor effect of 5-fluorouracil and gemcitabine on cholangiocarcinoma cells.
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Cell Line, Tumor; Cell Survival; Cholangiocarc | 2015 |
FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2015 |
Intraarterial 5-fluorouracil and interferon therapy is safe and effective for nonresectable biliary tract adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; | 2015 |
Capsaicin Enhances the Drug Sensitivity of Cholangiocarcinoma through the Inhibition of Chemotherapeutic-Induced Autophagy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy | 2015 |
Adjuvant Transarterial Chemoembolization Following Liver Resection for Intrahepatic Cholangiocarcinoma Based on Survival Risk Stratification.
Topics: Adult; Aged; Chemoembolization, Therapeutic; Cholangiocarcinoma; Enbucrilate; Epirubicin; Female; Fl | 2015 |
Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness.
Topics: Bile Duct Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cholangiocarcinoma; Deoxycytidi | 2015 |
Targeting the ∆133p53 isoform can restore chemosensitivity in 5-fluorouracil-resistant cholangiocarcinoma cells.
Topics: Aged; Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Blotting, Western; Cell Line, Tumor; Ce | 2015 |
TRAIL in Combination with Subtoxic 5-FU Effectively Inhibit Cell Proliferation and Induce Apoptosis in Cholangiocarcinoma Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bile Duct Neoplasms; Caspases; Cell Line, | 2015 |
A case of hepatoblastoma misdiagnosed as combined hepatocellular carcinoma and cholangiocarcinoma in an adult.
Topics: Adult; Carcinoma, Hepatocellular; Cholangiocarcinoma; Cisplatin; Diagnostic Errors; Doxorubicin; Dru | 2015 |
Sensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell Cultures.
Topics: Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Anilides; Animals; Antineoplastic Combined Chemot | 2015 |
Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; | 2016 |
Targeted delivery of 5-fluorouracil to cholangiocarcinoma cells using folic acid as a targeting agent.
Topics: Apoptosis; Cell Line, Tumor; Cholangiocarcinoma; Fluorouracil; Folic Acid; Humans; Nanomedicine; Nan | 2016 |
Inhibition of NF-κB Activity Enhances Sensitivity to Anticancer Drugs in Cholangiocarcinoma Cells.
Topics: Antineoplastic Agents; Apoptosis; ATP-Binding Cassette Transporters; Benzamides; Bile Duct Neoplasms | 2016 |
Photodynamic Therapy Plus Chemotherapy Compared with Photodynamic Therapy Alone in Hilar Nonresectable Cholangiocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma; Cispl | 2016 |
Irinotecan Plus Gemcitabine and Fluorouracil in Advanced Biliary Tract Cancer: A Retrospective Study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Ca | 2016 |
Upregulation of retinoic acid receptor-β reverses drug resistance in cholangiocarcinoma cells by enhancing susceptibility to apoptosis.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Bile Duct Neoplasms; Bile Ducts; Cell Line, Tum | 2016 |
[Efficacy of Combined Therapy(Drainage of the Bile Duct, High-Dose Hepatic Artery Infusion, and Radiation)for Hilar Cholangiocellularcarcinoma with Complete Portal Vein Obstruction].
Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Chemoradiotherapy; Cholangiocarcinoma; D | 2016 |
Characterization of 5-fluorouracil-resistant cholangiocarcinoma cell lines.
Topics: Cell Line, Tumor; Cholangiocarcinoma; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Regul | 2008 |
Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Cholangiocarcinom | 2009 |
[A case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha and 5-fluorouracil combined intra-arterial chemotherapy].
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chola | 2008 |
Epigallocatechin-gallate modulates chemotherapy-induced apoptosis in human cholangiocarcinoma cells.
Topics: Animals; Anticarcinogenic Agents; Apoptosis; Bile Duct Neoplasms; Blotting, Western; Camellia sinens | 2009 |
Oncolytic gene therapy combined with double suicide genes for human bile duct cancer in nude mouse models.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Antiviral Agents; Bile Duct Neoplasms; Bile | 2009 |
Impact of rhenium-188, gemcitabine, and 5-fluorouracil on cholangiocellular carcinoma cells: an in vitro study.
Topics: Analysis of Variance; Antimetabolites, Antineoplastic; Cell Cycle; Cholangiocarcinoma; Deoxycytidine | 2009 |
[A case of successful multimodal treatment for combined hepatocellular and cholangiocarcinoma with portal venous tumor thrombus].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2009 |
Combination of bilateral metal stenting and trans-stent photodynamic therapy for palliative treatment of hilar cholangiocarcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile D | 2010 |
Time to move to targeted drugs in biliary tract cancer?
Topics: Adenocarcinoma; Ampulla of Vater; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineo | 2010 |
Preliminary experience of cetuximab in the treatment of advanced-stage biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Abdominal irradiation modulates 5-Fluorouracil pharmacokinetics.
Topics: Abdominal Neoplasms; Animals; Antimetabolites, Antineoplastic; Area Under Curve; Cholangiocarcinoma; | 2010 |
Effects of thymidine phosphorylase on tumor aggressiveness and 5-fluorouracil sensitivity in cholangiocarcinoma.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Bile Duct Neoplasms; Carcinoma, Squamous Cell; Cell Line | 2010 |
Long-term culture following ES-like gene-induced reprogramming elicits an aggressive phenotype in mutated cholangiocellular carcinoma cells.
Topics: Animals; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Cultur | 2010 |
Outcome of patients receiving chemotherapy for advanced biliary tract or gallbladder carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla | 2010 |
Fatal immune haemolysis due to antibodies to individual metabolites of 5-fluorouracil.
Topics: Anemia; Anemia, Hemolytic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pro | 2010 |
Resveratrol enhances the sensitivity of cholangiocarcinoma to chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Cholangiocarcinoma; Cytochrome P-450 | 2010 |
Cytotoxic activity of Thai medicinal plants against human cholangiocarcinoma, laryngeal and hepatocarcinoma cells in vitro.
Topics: Antineoplastic Agents, Phytogenic; Atractylodes; Carcinoma, Hepatocellular; Cell Line, Tumor; Cholan | 2010 |
Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell | 2011 |
Cytotoxic activity of artemisinin derivatives against cholangiocarcinoma (CL-6) and hepatocarcinoma (Hep-G2) cell lines.
Topics: Antigens, CD; Antineoplastic Agents; Artemisinins; ATP Binding Cassette Transporter, Subfamily B; AT | 2011 |
COP35, a cholangiocarcinoma-binding oligopeptide, interacts with the clathrin heavy chain accompanied by GRP78.
Topics: Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cholangiocar | 2011 |
Neoadjuvant therapy protocol and liver transplantation in combination with pancreatoduodenectomy for the treatment of hilar cholangiocarcinoma occurring in a case of primary sclerosing cholangitis: case report with a more than 8-year disease-free survival
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Brachytherapy; Chemo | 2011 |
Adjuvant radio-chemotherapy for extrahepatic biliary tract cancers.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; | 2011 |
Polo-like kinase 1 inhibition as a new therapeutic modality in therapy of cholangiocarcinoma.
Topics: Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Deoxycyti | 2011 |
[Effectiveness of systemic chemotherapy of GEM+CBDCA+5-FU/LV and hepatic arterial infusion of CDDP in a case of advanced, combined hepatocellular-cholangiocarcinoma with multiple lung metastases].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2011 |
Acute inflammatory demyelinating polyradiculoneuropathy in a patient receiving oxaliplatin-based chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma; Fluorouraci | 2012 |
Chemotherapy for inoperable advanced or metastatic cholangiocarcinoma: retrospective analysis of 78 cases in a single center over four years.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrah | 2012 |
Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bile Duct Neoplasms; Bi | 2012 |
Orotate phosphoribosyl transferase mRNA expression and the response of cholangiocarcinoma to 5-fluorouracil.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Su | 2012 |
Fluoropyrimidines plus cisplatin versus gemcitabine/gemcitabine plus cisplatin in locally advanced and metastatic biliary tract carcinoma - a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; | 2012 |
Novel multimodality treatment sequencing for extrahepatic (mid and distal) cholangiocarcinoma.
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Brachytherapy; Chola | 2013 |
Adjuvant therapy for intrahepatic cholangiocarcinoma: the debate continues.
Topics: Adenocarcinoma; Adult; alpha-Fetoproteins; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers | 2012 |
[Combination therapy for inoperable cholangiocellular carcinoma-systemic chemotherapy and hepatic arterial injection].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chola | 2012 |
[Two long-term survival cases of unresectable intrahepatic cholangiocarcinoma treated with hepatic arterial infusion chemotherapy and radiation therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; | 2012 |
Challenge in differential diagnosis of a liver mass histologically defined as a metastatic lesion from an occult primary intestinal tumour. The importance of clinical findings and the limitations of histology and molecular profiles. A case report.
Topics: Adenoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intr | 2012 |
Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma.
Topics: Adult; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarc | 2002 |
Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma.
Topics: Adult; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarc | 2002 |
Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma.
Topics: Adult; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarc | 2002 |
Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma.
Topics: Adult; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarc | 2002 |
Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.
Topics: Administration, Oral; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Carcinoma, Hepato | 2004 |
Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.
Topics: Administration, Oral; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Carcinoma, Hepato | 2004 |
Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.
Topics: Administration, Oral; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Carcinoma, Hepato | 2004 |
Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.
Topics: Administration, Oral; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Carcinoma, Hepato | 2004 |
Movement of a novel serum tumour marker, RCAS1, in patients with biliary diseases.
Topics: Antigens, Neoplasm; Bile Ducts, Extrahepatic; Biliary Tract Neoplasms; Biomarkers, Tumor; CA-19-9 An | 2004 |
Cholangiocarcinoma: advocate an aggressive operative approach with adjuvant chemotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chemotherapy, | 2004 |
[Successful treatment for advanced cholangiocellular carcinoma with intrahepatic metastasis and/or portal vein tumor thrombi by intraarterial chemotherapy combined with 5-fluorouracil, adriamycin and cisplatin (FAP)--two cases report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; | 2004 |
Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chola | 2005 |
[The evaluation of chemoradiotherapy to unresectable hepatobiliary cancers].
Topics: Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Combined Modalit | 2005 |
[A case of unresectable cholangiocellular carcinoma treated with surgery followed by combination chemotherapy].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2005 |
Rapid resolution of liver metastasis from cholangiocarcinoma after bevacizumab with cisplatin and high-dose fluorouracil plus leucovorin.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2006 |
Tannic acid synergizes the cytotoxicity of chemotherapeutic drugs in human cholangiocarcinoma by modulating drug efflux pathways.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfami | 2007 |
[A case of intrahepatic cholangiocarcinoma effectively treated by hepatic arterial infusion chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Bone | 2006 |
[A 42-month disease free survival case of combined hepatocellular-cholangiocarcinoma with lymph node metastases treated with multimodal therapy].
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, | 2006 |
Effects of the anti-epidermal growth factor receptor antibody cetuximab on cholangiocarcinoma of the liver.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2007 |
Unexpected response to systemic chemotherapy in case of primarily nonresectable advanced disseminated intrahepatic cholangiocarcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic | 2007 |
Effects of targeting magnetic drug nanoparticles on human cholangiocarcinoma xenografts in nude mice.
Topics: Animals; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Fluorouracil; Humans; Ma | 2007 |
[A case of successful management of advanced cholangiocellular carcinoma by repeated hepatic resection].
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Hepatocel | 1996 |
Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepati | 1997 |
[The study of continuous infusion chemotherapy with low-dose cisplatin and 5-fluorouracil for patients with primary liver cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cholangiocarcinoma; | 1997 |
Long-term survival of a young woman with peripheral cholangiocarcinoma: a case report.
Topics: Adult; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chemotherapy, | 1999 |
[A case report: successful resection of advanced intrahepatic cholangiocarcinoma responding to preoperative hepatic artery infusion of 5-FU].
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; | 1999 |
Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma.
Topics: Antimetabolites, Antineoplastic; Brachytherapy; Cholangiocarcinoma; Disease Progression; Disease-Fre | 2000 |
Palliation of unresectable hilar cholangiocarcinoma.
Topics: Antimetabolites, Antineoplastic; Cholangiocarcinoma; Fluorouracil; Humans; Liver Neoplasms; Palliati | 2000 |
Arterial chemoinfusion therapy through an implanted port system for patients with unresectable intrahepatic cholangiocarcinoma--initial experience.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2002 |
Prognostic factors after pancreatoduodenectomy with extended lymphadenectomy for distal bile duct cancer.
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Chemotherapy, Adjuvant; Cholangiocarcinoma; Fe | 2002 |
[Conformal therapy of locally advanced cholangiocarcinoma of the main bile ducts].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2002 |
Capecitabine as second-line treatment for metastatic cholangiocarcinoma: a report of two cases.
Topics: Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Deoxycytidine | 2002 |
Limitations of conventional doses of chemoradiation for unresectable biliary cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, In | 2002 |